From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 24 Jul 2020 10:37:46 +0000

To: Jeremy Farrar

Subject: RE: Made it to UK press

I threw a brick!

From: Jeremy Farrar (b) (6)

Sent: Friday, July 24, 2020 4:47 AM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)

Subject: Made it to UK press

https://www.theguardian.com/sport/2020/jul/23/mlb-opening-night-fauci-yankees-nationals

Wellcome exists to improve health by helping great ideas to thrive. We support researchers, we take on big health challenges, we campaign for better science, and we help everyone get involved with science and health research. We are a politically and financially independent foundation.

The Wellcome Trust is a charity registered in England and Wales, no. 210183. Its sole trustee is The Wellcome Trust Limited, a company registered in England and Wales, no. 2711000 (whose registered office is at 215 Euston Road, London NW1 2BE, UK)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Jul 2020 16:28:01 +0000

To: Jeremy Farrar

Subject: RE: Hope you are OK

Thanks, Jeremy. I hope that I do not embarrass myself 😂

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone:
(b) (6)
FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jeremy Farrar (b) (6)

Sent: Tuesday, July 21, 2020 11:28 AM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)

Subject: Re: Hope you are OK

Enjoy



OFFICIAL STATEMENT

A STATEMENT FROM THE WASHINGTON NATIONALS REGARDING OPENING DAY

The Washington Nationals are thrilled to announce that Nats super-fan,
Dr. Anthony Fauci, Director of the National Institute of Allergy and Infectious
Diseases, has accepted our invitation to throw out the ceremonial
first pitch on Opening Day, Thursday, July 23.

Dr. Fauci has been a true champion for our country during the Covid-19 pandemic and throughout his distinguished career, so it is only fitting that we honor him as we kick off the 2020 season and defend our World Series Championship title.



From: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)

Date: Thursday, 9 July 2020 at 12:55

To: Jeremy Farrar (b) (6)

Subject: RE: Hope you are OK

Jeremy:

Thank you for your kind and considerate note. I am hanging in there, but it is not easy. Stay well and safe.

Warm regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone:
(b) (6)
FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not

accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jeremy Farrar (b) (6)

Sent: Thursday, July 9, 2020 7:37 AM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)

Subject: Hope you are OK

Watching events from a distance – all thoughts with you. Best wishes Jeremy

Wellcome exists to improve health by helping great ideas to thrive. We support researchers, we take on big health challenges, we campaign for better science, and we help everyone get involved with science and health research. We are a politically and financially independent foundation.

The Wellcome Trust is a charity registered in England and Wales, no. 210183. Its sole trustee is The Wellcome Trust Limited, a company registered in England and Wales, no. 2711000 (whose registered office is at 215 Euston Road, London NW1 2BE, UK)

From: Jeremy Farrar

Sent: Wed, 13 May 2020 21:25:59 +0000

To: Viner, Russell; Collins, Francis (NIH/OD) [E]; Fauci, Anthony (NIH/NIAID) [E]

Cc: Bianchi, Diana (NIH/NICHD) [E];Gibbons, Gary (NIH/NHLBI) [E]

Subject: Re: confidential - update on Paediatric Multisystem Inflammatory Syndrome

(PIMS)

Let us know if we can help

From: "Viner, Russell"

Date: Wednesday, 13 May 2020 at 22:22

To: Francis Collins

(b)(6), Jeremy Farrar
(b)(6), "Fauci,
Anthony (NIH/NIAID) [E]"
(b)(6)

Cc: "Bianchi, Diana (NIH/NICHD) [E]"
(b)(6)

Subject: Re: confidential - update on Paediatric Multisystem Inflammatory Syndrome (PIMS)

Dear Francis, Diana and Gary – and Jeremy Many thanks.

We have a unique opportunity to study this emerging phenomenon and ensure we have all the bases covered in terms of epi, mechanisms and treatment

I represent the Royal College of Paediatrics & Child Health who have had a role in coordinating responses here in the UK.

Colleagues here in the UK have networked extensively with other European countries in terms of sharing data and organising collection of research samples. I understand they have also linked with colleagues in the USA who particularly work on Kawasaki Disease - in Boston and San Diego.

I wonder if an international effort would be possible to pull together data across Europe and the USA – and ensure that we have adequately powered quality studies of epi, mechanisms and treatment. The number of cases will almost certainly preclude adequately powered studies in single countries, potentially even in the USA.

It appears that case numbers are now dropping in the UK/Europe – as the curve appeared to present and peak approximately a month after the covid peak – and I suspect a similar peak and decline will be seen in the USA if the post-infectious hypothesis is correct. Clearly more cases are likely with any secondary covid peaks

A collaboration between NIH and Wellcome could be very powerful in ensuring that this initial cluster from the first peak is well studied and prepare for prospective studies for future cases.

Treatment studies in particular might need to be international. None of the current covid-19 treatment studies would appear entirely appropriate as they stand

We have been planning an expert taskforce to oversee the research and clinical responses here in the UK – and it would make sense for this to be international given the above.

Yours and best

Russell

Dear Russell,

Thanks for your note and this additional information. I am looping in Dr. Diana Bianchi (Director, National Institute of Child Health and Human Development) and Dr. Gary Gibbons (Director, National Heart, Lung, and Blood Institute). I have asked them to cochair an urgent NIH team on PMIS. I am sure they will want to connect with you.

Best, Francis

From: Viner, Russell (b) (6)

Sent: Tuesday, May 12, 2020 6:12 PM

To: Jeremy Farrar (b) (6); Collins, Francis (NIH/OD) [E]

(b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6)

Subject: Re: confidential - update on Paediatric Multisystem Inflammatory Syndrome (PIMS)

Thanks Jeremy and hello to Francis and Tony

Colleagues here have been linked in with pediatric id/imm colleagues through Boston but a fully national collaborative approach would be very valuable.

We've started a national (across UK and Ireland) surveillance study using a well-established physician reporting system (British Paediatric Surveillance Unit, BPSU) – started yesterday, with weekly reporting by all paediatricians (95% coverage) in the UK - that will provide initially prevalence data next week/fortnight and then start to provide incidence data. Reported cases will be fed into established research systems to obtain biological specimens etc.

However cross national studies clearly much more useful if can be organised quickly. For epi, biological samples and treatment studies.

Re Rx - there is a recommendation to recruit to the multi-arm all-age Recovery Trial (https://www.recoverytrial.net) for more severe cases of this syndrome; however there is a concern that some of the arms may not be appropriate for this potentially post-covid syndrome – e.g. hydroxychloroquine or azithromycin. The standard treatment So there is the potential for a very rapid development of a pediatric rct – however this would be entirely underpowered in one country – and where a joint UK-USA plus others trial might be very powerful

Re etiology – a powerful prospective case-control design might be very useful in identifying environmental and other risk factors – again a single country study will be difficult to power.

The implications for vaccine development is something we've been discussing with Andy Pollard from the Oxford Vaccine Centre.

Keen to facilitate dialogue between UK and US teams. Let me know how we might do this.

Best
Russell

From: Jeremy Farrar (b) (6)

Date: Tuesday, 12 May 2020 at 19:33

To: Russell Viner (b) (6), Francis Collins (b) (6)

"Fauci, Anthony (NIH/NIAID) [E]" (b) (6)

Subject: Pay confidential, undete on Paydiatric Multiplicators Inflammatary)

Subject: Re: confidential - update on Paediatric Multisystem Inflammatory Syndrome (PIMS)

Russell

I shared your note with Francis Collins and Tony Fauci at NIH.

The NIH is looking at this in the USA – can we link you up with the teams in the USA?

Best wishes Jeremy

Syndrome (PIMS)

From: "Viner, Russell"

Date: Tuesday, 12 May 2020 at 13:16

To: "Vallance, Patrick (GO-Science)"

Chris"

(b) (6), Jeremy Farrar

(b) (6)

Cc: Natasha Neill

(b) (6)

Subject: confidential - update on Paediatric Multisystem Inflammatory

Dear Chris and Patrick, cc to Jeremy

I think you are also being updated by NHSE and perhaps also by Callum Semple but just a quick update from RCPCH perspective

We had an update call yesterday, which somewhat raised my level of concern and changed the picture slightly – so thought you should be in the picture. I have of course

real concerns about how we balance this with the issues about public confidence re schools.

Case definition: RCPCH case definition published Friday a week ago, now adopted in the UK and likely by WHO

Numbers – we appear to be close to 60 across the UK. One concern from the call yesterday was that there appears to be some milder forms sitting on paediatric wards – i.e. not fulfilling case definition but essentially children with very high CRP and a symptom or two. Discussions about revision to case definition – on hold for the moment. I am concerned that this will dilute the situation and artificially inflate figures.

Clinical picture: as before. There appear to be potentially 2-3 phenotypes; one with multisystem inflammatory symptoms, one with shock and perhaps one with essentially Kawasaki Disease (KD e.g. coronary artery aneurisms in young children) but refractory to treatment

Larger numbers coming from across the world, where COVID has been an issue. Italy, Spain, USA.

Deaths: 2 known deaths thus far, one London one Bristol. One was a 6 month old with refractory Kawasaki Disease (KD).

Severity - around 50% need PICU. As before

COVID status: I can't give you the exact new numbers, but unchanged i.e. a proportion around 25-30% test negative for virus but some later found to be serology positive (where this is available).

The particular concerns for me from yesterday were four:

- a. that some apparently very mild cases have been appearing as above potentially inflating the numbers, although these are also increasing for the full syndrome b. that some apparently very well children can suddenly deteriorate this is rare however
- c. some reports, without clear data, that cardiac abnormalities are more common than previously recognised when echoed. Raising concerns about longer term complications. d. Aetiology and risk factors: The higher proportion from BME backgrounds has been described before. A new concern was an apparently high proportion of parents who are healthcare workers. This is very concerning and I emphasised the need to recognise this is supposition, to collect good data and keep confidential for now until we have some actual data. However the potential to worry the public is very high.

Aetiology; remains unclear. Speculation that this is a post-inflammatory condition due to i) phenotype; ii) peaking 2-4 weeks after covid peak; iii) virus testing negative in some

patients. The absence of this syndrome in China/Japan/SK is puzzling, given that KD was described in Japan plus high prevalence there, presumably genetic.

This remains very much a mostly London phenomenon, with 1-2 cases only in Scotland and NI and a larger cluster in Wales. Which raises concerns about recognition. Note the occurrence in teenagers – and likely a syndrome that overlaps with young adults

Research

Brit Paediatric Surveillance Unit (BPSU) study started today. This is routine RCPCH rare disease surveillance methodology but will now run weekly to all paediatricians in the UK.

WHO is starting some surveillance as well – Uk people linked into this Routine recruitment into Diamonds/ISARIC studies of patients notified through BPSU.

However I believe that a more comprehensive research strategy is needed - e.g. encompassing a case-control study to examine risk factors such as ethnicity and parent occupation, deprivation etc. We are working very closely with NHSE and we have suggested that a formal joint Taskforce be formed to oversee the research and clinical responses. We hope Steve Powis will agree to this.

Publicity

An Italian description of 10 cases of a KD-like syndrome will appear in Lancet later today or tomorrow, with a commentary (by me and Liz Whittaker from Imperial – trying to balance the importance of recognising the new syndrome with the public health messages).

The UK experience has been submitted (NEJM).

These will undoubtedly raise public concern. The RCPCH is working hard to ensure that messages are clear and recognise the bigger, public health picture.

I hope this is helpful. Let me know if you wish further information or have advice for us.

Best Russell From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 12 May 2020 18:49:04 +0000

To: Jeremy Farrar Subject: Re: Take Care

Jeremy:

Thank you for your kind note. Much appreciated. (b) (6)

Best regards,

Tony

On May 12, 2020, at 12:57 PM, Jeremy Farrar

(b) (6) wrote:

Tony - Hope you are OK, take care, best wishes Jeremy

Wellcome exists to improve health by helping great ideas to thrive. We support researchers, we take on big health challenges, we campaign for better science, and we help everyone get involved with science and health research. We are a politically and financially independent foundation.

The Wellcome Trust is a charity registered in England and Wales, no. 210183. Its sole trustee is The Wellcome Trust Limited, a company registered in England and Wales, no. 2711000 (whose registered office is at 215 Euston Road, London NW1 2BE, UK)

From: Jeremy Farrar

Sent: Tue, 12 May 2020 17:42:11 +0000

To: Fauci, Anthony (NIH/NIAID) [E]; Collins, Francis (NIH/OD) [E]

Subject: FW: confidential - update on Paediatric Multisystem Inflammatory Syndrome

(PIMS)

Just to update.

Any news on this from US?

From: Viner, Russell	(b) (6)		
Sent: 12 May 2020 13:17			
To: Vallance, Patrick (GO-Sc	ience)	(b) (6); Whitty, Chris	
(b) (6) Jeremy Farrar	(b) (6)	
Cc: Natasha Neill	(b) (6)		

Subject: confidential - update on Paediatric Multisystem Inflammatory Syndrome (PIMS)

Dear Chris and Patrick, cc to Jeremy

I think you are also being updated by NHSE and perhaps also by Callum Semple but just a quick update from RCPCH perspective

We had an update call yesterday, which somewhat raised my level of concern and changed the picture slightly – so thought you should be in the picture. I have of course real concerns about how we balance this with the issues about public confidence re schools.

Case definition: RCPCH case definition published Friday a week ago, now adopted in the UK and likely by WHO

Numbers – we appear to be close to 60 across the UK. One concern from the call yesterday was that there appears to be some milder forms sitting on paediatric wards – i.e. not fulfilling case definition but essentially children with very high CRP and a symptom or two. Discussions about revision to case definition – on hold for the moment. I am concerned that this will dilute the situation and artificially inflate figures.

Clinical picture: as before. There appear to be potentially 2-3 phenotypes; one with multisystem inflammatory symptoms, one with shock and perhaps one with essentially Kawasaki Disease (KD e.g. coronary artery aneurisms in young children) but refractory to treatment

Larger numbers coming from across the world, where COVID has been an issue. Italy, Spain, USA.

Deaths: 2 known deaths thus far, one London one Bristol. One was a 6 month old with refractory Kawasaki Disease (KD).

Severity - around 50% need PICU. As before

COVID status: I can't give you the exact new numbers, but unchanged i.e. a proportion around 25-30% test negative for virus but some later found to be serology positive (where this is available).

The particular concerns for me from yesterday were four:

- a. that some apparently very mild cases have been appearing as above potentially inflating the numbers, although these are also increasing for the full syndrome
- b. that some apparently very well children can suddenly deteriorate this is rare however
- c. some reports, without clear data, that cardiac abnormalities are more common than previously recognised when echoed. Raising concerns about longer term complications.
- d. Aetiology and risk factors: The higher proportion from BME backgrounds has been described before. A new concern was an apparently high proportion of parents who are healthcare workers. This is very concerning and I emphasised the need to recognise this is supposition, to collect good data and keep confidential for now until we have some actual data. However the potential to worry the public is very high.

Aetiology; remains unclear. Speculation that this is a post-inflammatory condition due to i) phenotype; ii) peaking 2-4 weeks after covid peak; iii) virus testing negative in some patients. The absence of this syndrome in China/Japan/SK is puzzling, given that KD was described in Japan plus high prevalence there, presumably genetic.

This remains very much a mostly London phenomenon, with 1-2 cases only in Scotland and NI and a larger cluster in Wales. Which raises concerns about recognition.

Note the occurrence in teenagers – and likely a syndrome that overlaps with young adults

Research

Brit Paediatric Surveillance Unit (BPSU) study started today. This is routine RCPCH rare disease surveillance methodology but will now run weekly to all paediatricians in the UK.

WHO is starting some surveillance as well – Uk people linked into this

Routine recruitment into Diamonds/ISARIC studies of patients notified through BPSU.

However I believe that a more comprehensive research strategy is needed – e.g. encompassing a case-control study to examine risk factors such as ethnicity and parent occupation, deprivation etc. We are working very closely with NHSE and we have suggested that a formal joint Taskforce be formed to oversee the research and clinical responses. We hope Steve Powis will agree to this.

Publicity

An Italian description of 10 cases of a KD-like syndrome will appear in Lancet later today or tomorrow, with a commentary (by me and Liz Whittaker from Imperial – trying to balance the importance of recognising the new syndrome with the public health messages).

The UK experience has been submitted (NEJM).

These will undoubtedly raise public concern. The RCPCH is working hard to ensure that messages are clear and recognise the bigger, public health picture.

I hope this is helpful. Let me know if you wish further information or have advice for us.

Best

Russell

From:	Jeremy Farrar				
Sent:	Tue, 5 May 2020 12:00:28 +0000				
То:					
1 NT 10 NT 1	E];'Fore Henrietta';'Gao Fu';'Gashumba Diane';'Kaag Sigrid';'Suzuki Yasuhiro';'Vega				
	a Morales Jeanette';'Veronika Skvortsova';'VijayRaghavan Krishnaswamy'				
Cc:	'As Sy';'Gro'				
Subject:	Re: GPMB Board Teleconference; Tuesday 5 May 13.00-14.30 CEST				
Ian, Gro and As					
Apologies – I will have	to leave at 1pm UK time.				
Best wishes Jeremy					
From:	(b) (6)				
Date: Tuesday, 5 Mar	And the second s				
To: "SMITH, Ian Mich					
TOT SIVILLY IGHT WHEN	(b) (6), Jeremy Farrar (b) (6), 'Fauci Anthony'				
(b)	(6), 'Fore Henrietta' (b) (6), 'Gao Fu' (b) (6)				
Diane Gashumba	(b) (6), 'Kaag Sigrid' (b) (6) >, 'Suzuki Yasuhiro'				
	(b) (6) 'Vega Morales Jeanette' (b) (6), 'Vega				
Morales Jeanette	(b) (6), 'Veronika Skvortsova' (b) (6)				
'VijayRaghavan Krishi	Approximate the second				
Cc: 'As Sy'	(b) (6), 'Gro' (b) (6)				
	Board Teleconference; Tuesday 5 May 13.00-14.30 CEST				
Subject: AW. Or Mib !	Journal Telecomerence, Tuesday 5 May 15.00 14.50 eL51				
Dear Ian – thank y	ou very much for this. And thank you for the work of the				
688 - 655 199 A					
secretariat. I have	just two points.				
n					
Not each GPMB m	ember has a Sherpa (at least I don't)				
	(b) (5				

All the very best (until this afternoon) Ilona

Von: SMITH, Ian Michael (b) (6) Gesendet: Montag, 4. Mai 2020 13:38 An: 'Dzau Victor' < VDzau@nas.edu>; Chris.Elias (b) (6) J.Farrar (b) (6); 'Fauci Anthony' (b) (6); 'Fore Henrietta' (b) (6) >; 'Gao Fu' (b) (6); 'Gashumba Diane' (b) (6) 'Kaag (b) (6) >; 'Suzuki Yasuhiro' Sigrid' (b) (6); Ilona Kickbusch ; 'Vega Morales Jeanette' (b) (6); 'Vega Morales (b) (6); 'Veronika Skvortsova' (b) (6) 'VijayRaghavan Jeanette' (b) (6) Krishnaswamy' (b) (6); Gro (b)(6)Cc: 'As Sy' Betreff: RE: GPMB Board Teleconference; Tuesday 5 May 13.00-14.30 CEST

Dear GPMB co-chairs and members,

Please find attached a short report on the activities of the Board and secretariat for the period 1 January to 30 April 2020. This is provided for information only.

Regards,

lan

From: SMITH, Ian Michael Sent: Friday, May 1, 2020 5:23 PM To: 'Dzau Victor' < VDzau@nas.edu>; 'Elias Chris' (b) (6); 'Farrar Jeremy' (b) (6); 'Fauci Anthony' (b) (6); 'Fore Henrietta' (b) (6); 'Gao Fu' (b) (6): 'Gashumba Diane' (b) (6); 'Kaag Sigrid' (b) (6) >; 'Kickbusch Ilona' (b) (6) 'Suzuki Yasuhiro' < (b) (6) 'Vega Morales Jeanette' (b) (6); 'Vega Morales Jeanette' (b) (6); 'Veronika Skvortsova' (b) (6) 'VijayRaghavan (b) (6) Krishnaswamy' (b) (6); 'Brundtland Gro Harlem' (b) (6) Cc: 'As Sy' Subject: GPMB Board Teleconference; Tuesday 5 May 13.00-14.30 CEST

Dear Board members,

In preparation for the Board meeting on Tuesday 5 May from 13.00-14.30 CEST, please find attached the draft annotated outline of the Annual Report.

(b)(5)

You will also find copied below the call-in details.

We look forward to the meeting.

Regards,

lan

When it's time, join the Webex meeting here.

Meeting number (access code): (b) (6)

Meeting password: (b) (6),

Tuesday, May 5, 2020 1:00 pm | (UTC+02:00) Brussels, Copenhagen, Madrid, Paris | 1 hr 30 mins

Join meeting

Join by phone

Tap to call in from a mobile device (attendees only)

41445750282 SWITZERLAND Toll

+1-415-655-0003 US Toll

Global call-in numbers | Toll-free calling

restrictions

Need help? Go to http://help.webex.com

ay, April 29, 2020 8:18 PM



Dear Board members, dear colleagues,

Please find attached an annotated agenda for the Board teleconference scheduled for Tuesday 5 May from 13.00-14.30 CEST. In order to make as much time available as possible for discussion on the outline of the 2020 annual report, we have limited the number of topics for discussion.

Remaining documents for the meeting will be sent to you on Friday.

For those who have not yet done so, we would be grateful if you could confirm your participation in teleconference.

Many thanks,

lan

Ian Smith

(b) (6

Desk: +41 22 7913979

Mobile/WhatsApp:

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Apr 2020 22:35:34 +0000

To: Jeremy Farrar; Dzau, Victor J.; George GAO

Cc: Richard

(b) (6) Emma;Conrad,

Patricia (NIH/NIAID) [E];Teresa Miller de Vega (b) (6);Rebeka Yasmin -

CEPI;ben.tinker@cnn.com;Amanda.Sealy@cnn.com;Neel.Khairzada@turner.com;Tia.Miller@turner.com

(b) (6);McGinnis, J. Michael;Balatbat, Celynne;Mun, Jenny;

(b) (6);Redfield,

Robert R. (CDC/OD)

Subject: RE: NAS Annual Meeting Session on COVID-19 -- Information regarding your

Saturday April 25 participation

Jeremy:

Many thanks for the update. Please continue to keep me informed.

Best,

Tony

Anthony S. Fauci, MD

Director

National Institute of Allergy and Infectious Diseases

Building 31, Room 7A-03 31 Center Drive, MSC 2520 National Institutes of Health Bethesda, MD 20892-2520 Phone: (b) (6)

Phone: ((b) (6) FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jeremy Farrar	(b) (6)		
Sent: Tuesday, April 28, 2020 10	D:39 AM		
To: Fauci, Anthony (NIH/NIAID)	[E]	(b) (6) Dzau, Victor J. <vdz< td=""><td>au@nas.edu>; George</td></vdz<>	au@nas.edu>; George
GAO (b) (6)	(50) (20)	~ ~	
Cc: Richard Hatchett	(b) (6)	(b) (6)	
	(b) (6) Hannon, Emm	a <ehannon@nas.edu>; Co</ehannon@nas.edu>	nrad, Patricia
(NIH/NIAID) [E] <	(b) (6); Teresa N	Ailler de Vega	(b) (6);
(b) (6); Rebeka Yasmin - C	EPI	(b) (6); ben.tinker@cn	n.com;
Amanda.Sealy@cnn.com; Neel.	Khairzada@turner.co	om; Tia.Miller@turner.com;	(b) (6);
McGinnis, J. Michael	(b) (б)		(b) (6) Mun, Jenny
<jmun@nas.edu>;</jmun@nas.edu>	(b) (6); Redfield, Ro	bert R. (CDC/OD)	(b) (6)'>
Subject : Re: NAS Annual Meeting participation	ng Session on COVID-	19 Information regarding	your Saturday April 25

Quick update

Update in confidence

European network from this morning:

16 Paris, 2 Geneva, few Madrid last 10 days - nothing like this usually seen even with seasonal KD or TSS


Barcelona have slightly different experience of 6 'Kawasaki' in last 2 weeks - couple now who have large coronary aneurysms, as have one child South London and one in Bristol.

Most UK PICU have 1-2 of these type of cases

Phenotype seems Diarrhoea and abdominal pain, refractory shock then various degrees of heart involvement and inflammation ++ - several have had their normal appendix whipped out Most negative respiratory and stool PCR for anything, some positive resp PCR COVID - GOSH early case has seroconverted, but had immunoglobulin

We are establishing database UK and Europe and trying to define what the clinician features are and agree investigations.

Notably, none in US reported (just D/W Boston childrens who have been running shared international COVID experience web calls) and none in Rome, unsure about rest of Italy yet Does seem BAME preponderance -?? immune related or social phenomenon, in terms of deprivation prevalence and ability to isolate



Subject: RE: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

Jeremy:

Thanks for the heads up. Is there any more detailed description of the precise clinical manifestations? They describe a "multisystem inflammatory state". It is vasculitis or anything more specific? Could be an infectious agent that has nothing to do with SARS-CoV-2 infection even though some children are circumstantially infected with SARS-CoV-2or it could be a post-SARS-CoV-2 inflammatory syndrome, perhaps a Kawasaki syndrome-like disease. Please keep me informed if you hear any further information.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone:
(b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jeremy Farrar	(b) (6)			
Sent: Monday, April 27, 2020 7:13 AM				
To: Fauci, Anthony (NIH/NIAID) [E]		(b) (6); Dzau, Victor	J. < <u>VDzau@nas.edu</u> >	George
GAO (b) (6)				
Cc: Richard Hatchett	(b) (6);		(b) (6) (
(b) (6); H	lannon, Emm	na < EHannon@nas.e	du>; Conrad, Patricia	
(NIH/NIAID) [E]) (6); Teresa I	Miller de Vega		(b) (6);
(b) (6); Rebeka Yasmin - CEPI	(b) (6); ben.tinker@cnn.com;			
Amanda.Sealy@cnn.com; Neel.Khairza	da@turner.c	om; <u>Tia.Miller@turn</u>	er.com; hujr@chinacc	lc.cn;
McGinnis, J. Michael < MMcGinnis@nas	s.edu>;		(b) (6) Mun,	Jenny
<jmun@nas.edu>; (b) (6)</jmun@nas.edu>	9		4 (2007) (2-50-7)(100-6)	
Subject: Re: NAS Annual Meeting Session	on on COVID	-19 Information re	garding your Saturday	Anril 25

participation

To be aware of – news over night so a huge amount of uncertainty – important for COVID19 now, and a potential concern for how we view immunity, protection, post-infectious immunopathology.

https://www.hsj.co.uk/acute-care/exclusive-national-alert-as-coronavirus-related-condition-may-be-emerging-in-children/7027496.article

https://t.co/Bj6YHLJ8zi

From: "Fauci, Anthony (NIH/	NIAID) [E]"	(b) (6).	
Date: Sunday, 26 April 2020 a	nt 19:52		
To: Victor Dzau < VDzau@na	s.edu>, George Gao	(b) (б).	
Cc: Jeremy Farrar	(b) (6), Richard	Hatchett	(b) (6)
	(b) (6)	
"		(b)	(6)>, "Hannon,
Emma" < EHannon@nas.edu >	, "Conrad, Patricia (NIH/NI		(b) (6),
Teresa de Vega			(b) (6) Rebeka
Yasmin - CEPI	(b) (6), "ben.tinker(d	@cnn.com" <ben.tin< td=""><td>ker@cnn.com>,</td></ben.tin<>	ker@cnn.com>,
"Amanda.Sealy@cnn.com" <a< td=""><td>manda.Sealy@cnn.com>,</td><td>"Neel.Khairzada@t</td><td>turner.com"</td></a<>	manda.Sealy@cnn.com>,	"Neel.Khairzada@t	turner.com"
<neel.khairzada@turner.com< td=""><td>>, "Tia.Miller@turner.com"</td><td>" < Tia. Miller@turn</td><td>er.com>,</td></neel.khairzada@turner.com<>	>, "Tia.Miller@turner.com"	" < Tia. Miller@turn	er.com>,
	(b) (6) "McGinnis, J.	Michael" < MMcGi	nnis@nas.edu>,
	(b) (6) "Mun, Jenny	" <jmun@nas.edu></jmun@nas.edu>	,
	(b) (6)		
Subject: RE: NAS Annual Me	eeting Session on COVID-1	9 Information re	garding your

It was a real pleasure to join all of you on this important session. Many thanks for inviting me.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Dzau, Victor J. <<u>VDzau@nas.edu</u>> Sent: Saturday, April 25, 2020 3:59 PM

Saturday April 25 participation

Subject: Re: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

Dear Jeremy, Tony, Sanjay, George, Susan and Richard,

Thank you so much for your superb contributions. It was a spectacular session- a truly inspiring one. I am grateful to all of you.

Hope to see you soon.

Warmest regards,

Victor

On Apr 25, 2020, at 1:22 PM, George GAO (b) (6) wrote:

I am waiting for being connected and will use slides which were sent to your office George

发自我的iPhone

在 2020年4月24日,01:49,Dzau, Victor J. < VDzau@nas.edu > 写道:

Dear Jeremy, Tony, Sanjay, George, Susan, and Richard,


I'm really looking forward to this panel on COVID-19 at the NAS Annual Meeting on Saturday, April 25th at 2:00-3:30 pm ET. There is tremendous excitement and enthusiasm, and registration is through the roof.

I am sending this note to do a last minute check to see if there is anything you need from me. I also want to check whether you are planning to use slides. Will you be sending your slides to us to project or use the share screen feature to advance your own slides? Regardless, it would be helpful to me if you could send me your slides for my preparation.

I would greatly appreciate it if you would respond to this email.

Best,

PS, (b) (6), my special assistant, will be sending you additional information about the session logistics shortly.



Dear all,

Thank you for agreeing to participate in a special late breaking session on the COVID-19 pandemic at the NAS annual meeting. Knowing how busy you are, I am sending this email in lieu of a call to prepare for the session.

As you know, this is a 90 minute session which aims to provide our audience with deeper insights into the latest developments in the COVID-19 response. I plan to hold an engaging discussion that covers the whole experience on dealing with this pandemic – from US to international, to preparedness and response, the biology of the virus, the state of diagnostic, treatment and vaccine development, and the importance of communication.

I will begin the session by providing brief (~3 min) opening remarks describing the circumstances of the pandemic. Then, I will introduce the panelists and you will each have 7 minutes to provide remarks. You may use a limited number of slides for illustration. I hope that each panelist will provide their own perspective and speak to the issues proposed below.

- Jeremy Farrar will discuss the global response to the pandemic, drawing from his
 experience as a global leader, the chair of the Scientific Advisory Group for the WHO's
 R&D Blueprint and as a member of the Global Preparedness Monitoring Board.
- Tony Fauci will discuss the US pandemic and provide his perspective as a member of the White House Coronavirus Task Force addressing the 2019–20 coronavirus pandemic.
- George Gao will discuss China's response to the pandemic and lessons learned for the rest of the globe.

- Susan Weiss will discuss the viral characteristics of SARS COV2, insights into its pathobiology, immunity and development of a pan-CoV antiviral.
- Richard Hatchett will discuss the development of new vaccines and treatments against COVID-19.
- Sanjay Gupta will comment on the health system response to the pandemic and challenges related to communication and public engagement in responding to COVID-19.

Following remarks from each panelist, we will have a moderated discussion amongst ourselves – I will ask you a set of questions (15 mins) and then we will take questions from the web (25 mins). To prepare me to be your moderator, please send me any questions you would like me to ask you. For those of you who would like to have a prep call, please let me know and I will set it up.

Best, Victor

From: Mun, Jenny				
	pril 8, 2020 10:56 AM	1		
To:	(b) (6)	(b) (6)		(b) (6)
	(b) (6) ;			(b) (6)
Cc: Dzau, Victor J.;	(b) (б) ; M	un, Jenny ; Hannon, Emma ;		(b) (6);
	(b) (6) _K '		(b) (6)	'ben.tinker@cnn.com';
		da@turner.com' ; 'Tia.Miller@ COVID-19 Information rega		

Dear Speakers:

I am the logistical contact for the COVID-19 session that will be held as part of the Annual Meeting (online) program on Saturday, April 25 at 2:00 pm EDT. Thank you for agreeing to participate in this session. To help you with your planning, I have provided additional details below.

Please note that the session will be live webcast and the general public will also be able to watch the session. Video from the session will also be uploaded on the NAS YouTube channel (https://www.youtube.com/user/theNASciences) after the meeting. We will need to obtain signed speaker release forms for your participation in this session. I have attached the speaker release form for your review and submission. Please return the signed speaker release form by Monday, April 13.

Session speakers are asked to connect 30 minutes prior to the session start time (by Saturday, April 25 at 1:30 pm EDT) to allow the technical staff to check connections and prepare for the session. Details on how to connect will be sent before the meeting.

We will list you in our promotional materials as noted below. If this is incorrect, please let me know.

Anthony S. Fauci, Director, National Institute of Allergy and Infectious Diseases

Jeremy Farrar, Director, Wellcome Trust
George F. Gao, Director-General, Chinese Center for Disease Control & Prevention
Sanjay Gupta, Chief Medical Correspondent, CNN
Richard J. Hatchett, CEO, Coalition for Epidemic Preparedness Innovations
Susan R. Weiss, Professor of Microbiology, Perelman School of Medicine, University of Pennsylvania

Since many of us have moved to remote work environments, you may already be proficient with Zoom and other online meeting/collaboration applications. I am attaching a 'speaker guidelines' file in case you have any questions on how best to prepare for and stage your remote talk. We have technical staff available to help you become familiar with Zoom and its settings — such as "sharing your screen" (if you have slide presentations that need to be shown during your talk). We can arrange for a training session this week or next week. If you would like to schedule a session, please let me know as soon as possible.

Dr. Dzau's office will be in touch regarding the agenda for this session. If you have any other questions, please let me know.

Regards, Jenny

Jenny Mun Membership Director National Academy of Sciences

(b) (6)

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Apr 2020 12:33:44 +0000

To: Jeremy Farrar

Subject: RE: NAS Annual Meeting Session on COVID-19 -- Information regarding your

Saturday April 25 participation

Thanks, Jeremy. I saw the report in the Post from Saturday. These children had mostly respiratory disease and diarrhea. I will check with the docs at DC Children's Hospital about the presence of "multisystem inflammatory state". This could just be the advanced stage of their disease compatible with advanced SARS-COV-2

Best, Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone:
(b) (6)
FAX: (301) 496-4409
E-mail:
(b) (6)


The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jeremy Farrar	(b) (6)		
Sent: Monday, April 27, 2020 7:38 AM	5 65 7 7 7 7 7		
	<u>E</u>	V	
To: Fauci, Anthony (NIH/NIAID) [E]		(b) (6); Dzau, Victor J. <vdza< td=""><td>au@nas.edu>; George</td></vdza<>	au@nas.edu>; George
GAO (b) (6)			application of the second seco
Cc: Richard Hatchett	(b) (6)	(b) (6);	
(b) (6);	Hannon, Emm	a <ehannon@nas.edu>; Cor</ehannon@nas.edu>	rad, Patricia
(NIH/NIAID) [E]	(b) (6); Teresa N	Ailler de Vega	(b) (6)
(b) (6); Rebeka Yasmin - CEPI		(b) (6):>; ben.tinker@cnr	n.com;
Amanda.Sealy@cnn.com; Neel.Khairza	ada@turner.co	om; Tia.Miller@turner.com;	(b) (6);
McGinnis, J. Michael	(b) (6) >;		(b) (6) Mun, Jenny
(b) (6 Redfield, Ro	bert R. (CDC/OD) <	(b) (6)
Subject: Re: NAS Annual Meeting Sess participation	ion on COVID-	19 Information regarding	your Saturday April 2!

Thanks Tony – have asked for that and will share as soon as I can.

I believe there have been reports in the Washington Post.

https://www.washingtonpost.com/local/new-dc-hospital-numbers-suggest-kids-do-face-some-risk-of-coronavirus-hospitalization/2020/04/25/5e78c268-86fe-11ea-878a-86477a724bdb story.html



Subject: RE: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

Jeremy:

Thanks for the heads up. Is there any more detailed description of the precise clinical manifestations? They describe a "multisystem inflammatory state". It is vasculitis or anything more specific? Could be an infectious agent that has nothing to do with SARS-CoV-2 infection even though some children are circumstantially infected with SARS-CoV-2or it could be a post-SARS-CoV-2 inflammatory syndrome, perhaps a Kawasaki syndrome-like disease. Please keep me informed if you hear any further information.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jeremy Farrar (b)(6)Sent: Monday, April 27, 2020 7:13 AM To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Dzau, Victor J. <<u>VDzau@nas.edu</u>>; George GAC (b) (6) (b) (6) Cc: Richard Hatchett (b) (6): (b) (6); Hannon, Emma < EHannon@nas.edu>; Conrad, Patricia (b) (6): Teresa Miller de Vega (NIH/NIAID) [E] (b) (6); (b) (6); Rebeka Yasmin - CEPI (b) (6); ben.tinker@cnn.com; Amanda.Sealy@cnn.com; Neel.Khairzada@turner.com; Tia.Miller@turner.com; hujr@chinacdc.cn: McGinnis, J. Michael (b) (6) Mun, Jenny (b) (6) <JMun@nas.edu>

Subject: Re: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

To be aware of – news over night so a huge amount of uncertainty – important for COVID19 now, and a potential concern for how we view immunity, protection, post-infectious immunopathology.

https://www.hsj.co.uk/acute-care/exclusive-national-alert-as-coronavirus-related-condition-may-be-emerging-in-children/7027496.article

https://t.co/Bj6YHLJ8zi

```
From: "Fauci, Anthony (NIH/NIAID) [E]"
                                                               (b) (6).
Date: Sunday, 26 April 2020 at 19:52
To: Victor Dzau <\rightarrow\text{Dzau@nas.edu}\rightarrow\text{George Gao}
                                           (b) (6), Richard Hatchett
                                                                                          (b) (6)
Cc: Jeremy Farrar
                       (b) (6)"
                                                        (b) (6)
                                                                            (b) (6), "Hannon,
                                                                                            (b) (6).
Emma" < EHannon@nas.edu>, "Conrad, Patricia (NIH/NIAID) [E]"
Teresa de Vega
                                                                              (b) (6) >, Rebeka
                                       (b) (6), "ben.tinker@cnn.com" < ben.tinker@cnn.com>,
Yasmin - CEPI
"Amanda.Sealy@cnn.com" < Amanda.Sealy@cnn.com>, "Neel.Khairzada@turner.com"
<Neel.Khairzada@turner.com>, "Tia.Miller@turner.com" <Tia.Miller@turner.com>,
                                      (b) (6) "McGinnis, J. Michael" < MMcGinnis@nas.edu>,
```

```
(b) (6) >, "Mun, Jenny" < <u>JMun@nas.edu</u>>,
```

Subject: RE: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

It was a real pleasure to join all of you on this important session. Many thanks for inviting me.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Dzau, Victor J. <VDzau@nas.edu> Sent: Saturday, April 25, 2020 3:59 PM To: George GAO Cc: Fauci, Anthony (NIH/NIAID) [E] (b)(6)(b) (6): (b) (6) (b) (6); WEISSSR@pennmedicine.upenn.edu; Hannon, Emma < EHannon@nas.edu >; Conrad, Patricia (NIH/NIAID) [E] (b) (6) (b) (6) ben.tinker@cnn.com; Amanda.Sealy@cnn.com; Neel.Khairzada@turner.com; Tia.Miller@turner.com; (b) (6) (b) (6) Mun, Jenny McGinnis, J. Michael < MMcGinnis@nas.edu> (b) (6) haja.bally@cepi.net

Subject: Re: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

Dear Jeremy, Tony, Sanjay, George, Susan and Richard,

Thank you so much for your superb contributions. It was a spectacular session- a truly inspiring one. I am grateful to all of you.

Hope to see you soon.

Warmest regards,

Victor

On Apr 25, 2020, at 1:22 PM, George GAO (b) (6) wrote:

I am waiting for being connected and will use slides which were sent to your office George

发自我的iPhone

在 2020年4月24日, 01:49, Dzau, Victor J. < VDzau@nas.edu > 写道:

Dear Jeremy, Tony, Sanjay, George, Susan, and Richard,

I'm really looking forward to this panel on COVID-19 at the NAS Annual Meeting on Saturday, April 25th at 2:00-3:30 pm ET. There is tremendous excitement and enthusiasm, and registration is through the roof.

I am sending this note to do a last minute check to see if there is anything you need from me. I also want to check whether you are planning to use slides. Will you be sending your slides to us to project or use the share screen feature to advance your own slides? Regardless, it would be helpful to me if you could send me your slides for my preparation.

I would greatly appreciate it if you would respond to this email.

Best, Victor

PS, (b) (6), my special assistant, will be sending you additional information about the session logistics shortly.

```
From: Dzau, Victor J. <VDzau@nas.edu>
Sent: Thursday, April 9, 2020 11:01 AM
                                                     (b) (6)
                                                                              (b) (6)
To: Mun, Jenny <JMun@nas.edu>; '
                      (b) (6)
                                                                               (b) (6) 1
                                                  (b) (6);
                         (b) (6)
                                                     (b) (6)
                                                                                    (b) (6)
                                                                     (b) (6)
                                        (b) (6) Hannon, Emma < EHannon@nas.edu>;
Cc:
                     (b) (6)
                                                 (b) (6)
                                                                                    (b) (6)
                             'ben.tinker@cnn.com' <ben.tinker@cnn.com>; 'Amanda.Sealy@cnn.com'
<Amanda.Sealy@cnn.com>; 'Neel.Khairzada@turner.com' <Neel.Khairzada@turner.com>;
'Tia.Miller@turner.com' <Tia.Miller@turner.com>;
                                                                                       (b) (6)
```

Subject: RE: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

Dear all,

Thank you for agreeing to participate in a special late breaking session on the COVID-19 pandemic at the NAS annual meeting. Knowing how busy you are, I am sending this email in lieu of a call to prepare for the session.

As you know, this is a 90 minute session which aims to provide our audience with deeper insights into the latest developments in the COVID-19 response. I plan to hold an engaging discussion that covers the whole experience on dealing with this pandemic – from US to international, to preparedness and response, the biology of the virus, the state of diagnostic, treatment and vaccine development, and the importance of communication.

I will begin the session by providing brief (~3 min) opening remarks describing the circumstances of the pandemic. Then, I will introduce the panelists and you will each have 7 minutes to provide remarks. You may use a limited number of slides for illustration. I hope that each panelist will provide their own perspective and speak to the issues proposed below.

- Jeremy Farrar will discuss the global response to the pandemic, drawing from his
 experience as a global leader, the chair of the Scientific Advisory Group for the WHO's
 R&D Blueprint and as a member of the Global Preparedness Monitoring Board.
- Tony Fauci will discuss the US pandemic and provide his perspective as a member of the White House Coronavirus Task Force addressing the 2019–20 coronavirus pandemic.
- George Gao will discuss China's response to the pandemic and lessons learned for the rest of the globe.
- Susan Weiss will discuss the viral characteristics of SARS COV2, insights into its pathobiology, immunity and development of a pan-CoV antiviral.
- Richard Hatchett will discuss the development of new vaccines and treatments against COVID-19.
- Sanjay Gupta will comment on the health system response to the pandemic and challenges related to communication and public engagement in responding to COVID-19.

Following remarks from each panelist, we will have a moderated discussion amongst ourselves – I will ask you a set of questions (15 mins) and then we will take questions from the web (25 mins). To prepare me to be your moderator, please send me any questions you would like me to ask you. For those of you who would like to have a prep call, please let me know and I will set it up.

Best, Victor

From: Mun, Jenny

Sent: Wednesday, April 8, 2020 10:56 AM

To: (b) (6) (b) (6)

(b) (6)		(b) (6)
Cc: Dzau, Victor J.;	(6) (6); Mun, Jenny; Hannon, Emma;	(b) (6)
(b)		(b) (6) 'ben.tinker@cnn.com'

'Amanda.Sealy@cnn.com'; 'Neel.Khairzada@turner.com'; 'Tia.Miller@turner.com' **Subject:** NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25 participation

Dear Speakers:

I am the logistical contact for the COVID-19 session that will be held as part of the Annual Meeting (online) program on Saturday, April 25 at 2:00 pm EDT. Thank you for agreeing to participate in this session. To help you with your planning, I have provided additional details below.

Please note that the session will be live webcast and the general public will also be able to watch the session. Video from the session will also be uploaded on the NAS YouTube channel (https://www.youtube.com/user/theNASciences) after the meeting. We will need to obtain signed speaker release forms for your participation in this session. I have attached the speaker release form for your review and submission. Please return the signed speaker release form by Monday, April 13.

Session speakers are asked to connect 30 minutes prior to the session start time (**by Saturday, April 25 at 1:30 pm EDT**) to allow the technical staff to check connections and prepare for the session. Details on how to connect will be sent before the meeting.

We will list you in our promotional materials as noted below. If this is incorrect, please let me know.

Anthony S. Fauci, Director, National Institute of Allergy and Infectious Diseases
Jeremy Farrar, Director, Wellcome Trust
George F. Gao, Director-General, Chinese Center for Disease Control & Prevention
Sanjay Gupta, Chief Medical Correspondent, CNN
Richard J. Hatchett, CEO, Coalition for Epidemic Preparedness Innovations
Susan R. Weiss, Professor of Microbiology, Perelman School of Medicine, University of Pennsylvania

Since many of us have moved to remote work environments, you may already be proficient with Zoom and other online meeting/collaboration applications. I am attaching a 'speaker guidelines' file in case you have any questions on how best to prepare for and stage your remote talk. We have technical staff available to help you become familiar with Zoom and its settings — such as "sharing your screen" (if you have slide presentations that need to be shown during your talk). We can arrange for a training session this week or next week. If you would like to schedule a session, please let me know as soon as possible.

Dr. Dzau's office will be in touch regarding the agenda for this session. If you have any other questions, please let me know.

Regards, Jenny

Jenny Mun Membership Director National Academy of Sciences

jmun@nas.edu (b) (6)

From: Jeremy Farrar

Sent: Fri, 24 Apr 2020 16:55:47 +0000

To: SMITH, Ian Michael; 'Dzau Victor'; Chris. Elias; Fauci, Anthony (NIH/NIAID) [E]; 'Fore Henrietta'; 'Gao Fu'; 'Gashumba Diane'; 'Kaag Sigrid'; Ilona Kickbusch; 'Suzuki Yasuhiro'; 'Vega Morales Jeanette'; 'Veronika Skvortsova'; 'Vijay Raghavan Krishnaswamy'

Cc: 'As Sy';Gro

Subject: Re: Statement from the GPMB Co-chairs on the Access to COVID-19 Tools

Accelerator

Thank you

From: "SMITH, Ian Michael" (b) (6) Date: Friday, 24 April 2020 at 16:08 To: Victor Dzau <VDzau@nas.edu>, "Chris.Elias" (b) (6), Jeremy (b) (6), 'Fauci Anthony' (b) (6), 'Fore Henrietta' Farrar (b) (6), Diane Gashumba (b) (6), 'Gao Fu' (b) (6) >, Ilona Kickbusch (b) (6), 'Suzuki Yasuhiro' 'Kaag Sigrid' (b) (6), 'Vega Morales Jeanette' (b) (6), 'Vega (b) (6), 'Veronika Skvortsova' (b) (6) >. Morales Jeanette (b) (6) > 'VijayRaghavan Krishnaswamy' (b) (6), Gro (b) (6) Cc: 'As Sy'

Subject: Statement from the GPMB Co-chairs on the Access to COVID-19 Tools Accelerator

Dear Board members,

Today, WHO and many partners launched the Access to COVID-19 Tools (ACT) Accelerator, a global collaboration mechanism to accelerate development, production and deployment of safe and effective technologies to prevent, diagnose and treat COVID-19. The GPMB co-Chairs have issued the attached statement welcoming the initiative.

We encourage you to circulate the attached statement through your channels and networks.

With kind regards,

lan

Ian Smith

(b) (6)

Desk: +41 22 7913979

Mobile/WhatsApp: (b) (6

From: Teresa Miller de Vega on behalf of "Jeremy Farrar" (b) (6)

Sent: Wed, 22 Apr 2020 13:38:32 +0000

To: Collins, Francis (NIH/OD) [E]; Fauci, Anthony (NIH/NIAID) [E]; Dzau, Victor J.

Subject: CALL: T. Fauci, F. Collins, V. Dzau & J. Farrar

Join Microsoft Teams Meeting

(b) (6) United Kingdom, London (Toll)

Conference ID: (b) (6)

Local numbers | Reset PIN | Learn more about Teams | Meeting options

Join with a video conferencing device

(b) (6) VTC Conference ID: (b) (6)

Alternate VTC dialing instructions

Wellcome exists to improve health by helping great ideas to thrive. We support researchers, we take on big health challenges, we campaign for better science, and we help everyone get involved with science and health research. We are a politically and financially independent foundation.

The Wellcome Trust is a charity registered in England and Wales, no. 210183. Its sole trustee is The Wellcome Trust Limited, a company registered in England and Wales, no. 2711000 (whose registered office is at 215 Euston Road, London NW1 2BE, UK)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 8 Apr 2020 13:19:09 +0000

To: Jeremy Farrar Subject: RE: COVID

Jeremy:

Many thanks for your kind note. Much appreciated. Running on fumes, but still running. Hope to chat with you soon to catch up.

Warm regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jeremy Farrar (b) (6)

Sent: Tuesday, April 7, 2020 5:14 PM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)

Subject: COVID

Tony

Hope you are OK

Thank you, again, for your remarkable leadership – best wishes Jeremy

Wellcome exists to improve health by helping great ideas to thrive. We support researchers, we take on big health challenges, we campaign for better science, and we help everyone get involved with science and health research. We are a politically and financially independent foundation.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 26 Mar 2020 02:26:41 +0000

To: Jeremy Farrar Subject: RE: COVID19

OK. Let us talk over the weekend.

From: Jeremy Farrar (b) (6)

Sent: Wednesday, March 25, 2020 4:32 PM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)

Subject: Re: COVID19

Sorry Tony....

Cannot tonight I am afraid.

Weekends marginally few things on - if better for you!

My number is:

(b) (6)

Jeremy

From: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)

Date: Wednesday, 25 March 2020 at 13:15
To: Jeremy Farrar (b) (6)

Subject: RE: COVID19

Will call before 9:00 AM EST. I cannot find your cell phone number. Please send it to me by e-mail

Anthony S. Fauci, MD

Director

National Institute of Allergy and Infectious Diseases

Building 31, Room 7A-03 31 Center Drive, MSC 2520 National Institutes of Health Bethesda, MD 20892-2520 Phone: (30 (b) (6) FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not

accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jeremy Farrar	(b) (6
and the second s	

Sent: Wednesday, March 25, 2020 8:23 AM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)

Subject: COVID19

Tony

Good to hear you on these WHO calls.

And your leadership in USA!

If you have time for a 5 min update let me know – very best wishes Jeremy

Physically Distanced, socially connected

Wellcome exists to improve health by helping great ideas to thrive. We support researchers, we take on big health challenges, we campaign for better science, and we help everyone get involved with science and health research. We are a politically and financially independent foundation.

Sent: Fri, 13 Mar 2020 21:27:36 +0000

To: Fauci, Anthony (NIH/NIAID) [E]; Victor Dzau

Subject: Washington

Tony

A privilege to know you and to observe and learn from your leadership, particularly over the last few weeks in the media and elsewhere.

I may be in Washington on Wednesday and Thursday next week, with a few meetings, seeing Victor etc – assuming still possible to fly UK-USA.

You are 24/7 I know, but if you had anytime, always great to see you.


Best wishes Jeremy

Wellcome exists to improve health by helping great ideas to thrive. We support researchers, we take on big health challenges, we campaign for better science, and we help everyone get involved with science and health research. We are a politically and financially independent foundation.

From: Jeremy Farrar Sent: Fri, 6 Mar 2020 14:33:45 +0000 (b) (6); Alex Harris; 'Esveld, Marja'; 'Gro Brundtland'; 'As To: (b) (6); Fauci, Anthony (NIH/NIAID) [E]; 'Fore Sy';'Dzau, Victor J.'; Henrietta';'Gao Fu';'Gashumba Diane';'R';'Suzuki Yasuhiro' (b) (6); 'Vega Morales Jeanette';'VijayRaghavan Krishnaswamy';'Skvortsova Veronika' 'SCHWARTLANDER, Bernhard F.';'Pate Muhamed';'Amelie RIOUX';'Tore Cc: Godal';'Godal, Tore (b) (6); RYAN, Michael J.; Kanarek, Morgan' (b) (6); Conrad, Patricia (NIH/NIAID) (b) (6); (b) (6); 'Sheila Austria'; William [E] Hall; Teresa Miller de Vega; Marston, Hilary (NIH/NIAID) [E] (b) (6) 'Zacharie Gahungu'; 'DSO'; 'GEV'; 'Gonggrijp, Mette' ;'Toomas Palu';Edward Whiting;Alice Jamieson Re: URGENT - GPMB COVID-19 FUNDING NOTE Subject: Agree, very positive and appreciated (b) (6) From: Date: Friday, 6 March 2020 at 14:13 To: Alex Harris (b) (6) (b) (6) 'Gro Brundtland' (b) (6), 'As Sy' (b) (6) (b) (6), Victor Dzau < VDzau@nas.edu>, (b) (6), Jeremy Farrar (b) (6), 'Anthony Fauci' (b) (6), 'Gao Fu' (b) (6) (b) (6), 'Fore Henrietta' (b) (6) 'Suzuki Yasuhiro' < Diane Gashumba (b) (6), 'R (b) (б) >, 'Vega (b) (6), 'VijayRaghavan Krishnaswamy' Morales Jeanette' (b) (6), 'Skvortsova Veronika' (b) (6), 'Pate Muhamed' Cc: Bernhard Schwartländer (b) (6), 'Amelie RIOUX' (b) (6), 'Tore Godal' (b) (6), "'Godal, Tore" (b) (6), Michael RYAN (b) (6), "'Kanarek, Morgan'" (b) (6) (b) (6) (b) (6) (b) (6) Scott Dowell (b) (6) Sheila Austria' (b) (6):> William Hall (b) (6), Teresa de Vega (b) (6) (b) (6) 'Marston Hilary' (b)(6)(b) (6)

'Zacharie Gahungu'	(b) (б), 'DSO'	(b) (б) 'GEV'
(b) (6) "'Go	nggrijp, Mette'"	(b) (6)
'Toomas Palu'	(b) டு, Edward Whiting	டு டு, Alice
Jamieson	(b) (6)	
Subject: AW: URGENT - 0	SPMB COVID-19 FUNDING NOTE	

Wonderful news Ilona



Dear Marja,

This is very good news and we greatly appreciate Minister Kaag's flexibility and support on this. With very best wishes,

Alex

Alex Harris

Head of Global Policy & Advocacy

Wellcome

```
(b) (6)
(b) (6)
```

From: Esve	eld, Marja	(b) (6)			
Sent: 06 M	larch 2020 10:34				
To: Alex Ha	arris	(b) (6); Gro Bru	ındtland	(b) (6)	As Sy
	(b) (6) >; Dzau, V	ictor J. < <u>VDzau@</u>	nas.edu>;		(b) (6); Jeremy
Farrar <	(b) (6) _;	Anthony Fauci	(b) (6)>; Fore Hen	rietta
	(b) (6); Gao Fu	(b) (6) >;	Gashumba Diane		(b) (6); R
	(b) (6); Ilona Kickbusch		(b) (6) Suzuki Ya	suhiro < (b) (6)	
		(b)	(6); Vega Morales	Jeanette	(b) (6) >;
VijayRagha	van Krishnaswamy	(b)	(6); Skvortsova Ve	eronika	(b) (6)
Cc: SCHWA	ARTLANDER, Bernhard		(b) (6); Pate	Muhamed	
	(b) (6); Amelie F	RIOUX	(b) (6);	ore Godal	(b) (6)
Godal, Tor	e		(b) (6)	RYAN, Michael	J,
	(b) (6); Kanarek, Morga	in			(b) (б)'
				(b) (6)	
		'Sheila Austria'			(b) (6); William Hall
	(b) (6); Teresa	Miller de Vega		(b) (б); 'Marston Hilary'
	(b) (6);	(b) (6)		(b)) (6)
		; Zacharie Ga	hungu		(b) (6); DSO
	(b) (6) >; GEV	(b) (6) Gong	grijp, Mette		(b) (6);
					(b) (6)
		Toomas Palu		(b) (6); Edwar	d Whiting
	(b) (6); Alice	Jamieson		(b) (6)	100 N 100 100 100 100 100 100 100 100 10
Subject: RI	: URGENT - GPMB COVII		OTF		

Dear all, sorry to bother you again but after careful considerations internally, I am happy to confirm that our Minister is willing to sign the letter.

```
(b) (5)
```

Kind regards, Marja

From: Esveld, Marja

Sent: vrijdag 6 maart 2020 09:23

To: 'Alex Harris'	(b) (6); Gro Brundtland	(b) (6); As Sy
(b) (6) >; Dzau, Vic	tor J. < <u>VDzau@nas.edu</u> >;	(b) (6) Jeremy
Farrar (b) (6) >; A	nthony Fauci (b) (6); Fore Henrietta
(b) (6); Gao Fu	(ნ) (ნ) >; Gashumba Diane	(b) (6); R
(b) (б); Ilona Kickbusch	(b) (6); Suzuki Ya	
	(6) (6); Vega Morales .	Jeanette (b) (6);
VijayRaghavan Krishnaswamy	(b) (6) Skvortsova Ve	ronika (b) (6) >
Cc: SCHWARTLANDER, Bernhard F.	(b) (б)>; Pate	
(b) (б); Amelie RI	-	ore Godal (b) (6) >;
Godal, Tore		RYAN, Michael J.
(b) (б); Kanarek, Morgan		(b) (6)
	Sheila Austria'	(b) (6) >; William Hall
(b) (6); Teresa N	liller de Vega	(b) (6) 'Marston Hilary' (b) (6)
	Zacharie Gahungu	(b) (6) >; DSO
(b) (6); GEV	(b) (6) Gonggrijp, Mette	(b) (6)
	Conggrijp) mette	
	; Toomas Palu	(b) (6); Edward Whiting
(b) (6); Alice		(b) (6)
Subject: RE: URGENT - GPMB COVID-		
Dear Alex and others,		
,		
Although it has not been possible yet	to discuss the letter and note wi	th our Minister, I would like to
give you a		(b) (5)
		. We certainly
see the need for investments in R&D	and other important - underserv	ved – areas related to the current
outbreak,		(b) (5
		(b) (5)
		42.65
I will keep you updated,		(b) (5)
		(b) (5)
5 2		
Kind regards,		
Marja		
From: Alex Harris	(b) (6)	
Sent: donderdag 5 maart 2020 15:29		
10. -		
To: Gro Brundtland	(b) (6); As Sy	(b) (6); Dzau, Victor J.
To: Gro Brundtland VDzau@nas.edu ;		(b) (6); Dzau, Victor J. (b) (6)

(6) (6); Gashumba Diane	(b) (6); R	(b) (б); Ilona	Kickbusch
	(b) (6); Suzuki Yasuhiro	O	6)(6);	
	(b) (6) Vega Morales Jean	ette	(b) (6); VijayRagha	van
rishnaswamy	(b) (6); Skvortsov	va Veronika	(b) (6) >	
c: SCHWARTLAN	DER, Bernhard F.	(b) (6)>; Pate N	∕luhamed	
	(b) (6); Amelie RIOUX	(b) (6); To	ore Godal	(b) (6) >;
iodal, Tore		(b) (6)	RYAN, Michael J.	
(b) (6); Kanarek, Morgan			(b) (6)
	'Sheila Austri	a'		>; William Hall
	(b) (б); Teresa Miller de Vega		(b) (б); 'M	arston Hilary'
			(b) (б)	
	Zacharie () (6); Esveld,
/larja	(b) (6); DSO	(b) (6) >; GEV		onggrijp, Mette) (6)
			Toomas Palu	
	(b) (6) >; Edward Whiting	(b) (6)	>; Alice Jamieson	
	(b) (6)			
hank you for you	r input on the call yesterday reg	arding the COVID-19		(b) (4)
•				
				(b
0.85 0.06 0.08				
ith many thanks				

Alex

Alex Harris Head of Global Policy & Advocacy Wellcome


T:	(b) (6)
	(b) (6)

G7 leaders and Sherpas

Country	Rep	Sherpa (amendments welcome)	GPMB lead(s)
Canada	Justin Trudeau, Prime Minister	(b)	(6)
France	Emmanuel Macron, President		
Germany	Angela Merkel, Chancellor		Jeremy Farrar
Italy	Giuseppe Conte, Prime Minister		į
Japan	Shinzō Abe, Prime Minister		1
United Kingdom	Boris Johnson, Prime Minister		Jeremy Farrar
United States	Donald Trump, President		Victor Dzau
Participants			
European Union	Charles Michel, President of the European Council		
European Union	Ursula von der Leyen, President of the European Commission		Victor Dzau Jeremy Farrar

International financial institutions

Institution	Leadership	Sherpa/equivalent or suggested contacts	GPMB lead
		(b) (6), (b)	Victor Dzau
			As Sy



From: Alex Harris					
Sent: 03 March 203	20 23:06				
To: 'Amelie RIOUX'		(b) (6) >; [Dzau, Victor J. < <u>VDza</u>	u@nas.edu>;	
	(b) (6)	Jeremy Farra	r	(b) (6); Anthony F	auci
	(b) (6); Fore Hen	rietta	(b) (6) Gao Fi	(b)	6)>; Gashumba
Diane		(b) (6)	ona Kickbusch	(b) (6)	; Suzuki Yasuhiro
	(b) (6);		(b) (6) Vega	a Morales Jeanette	
(ы (6); VijayRagh	avan Krishna	swamy	(b) (6): Skvorts	ova Veronika
	(b) (6)				
Cc: Gro Brundtland		(b) (6); As	Sy	(b) (6) >; Elhadj SY	
(b) (6; Tore Godal	((b) (6) >; Godal, Tore	(b) (6)	;
		SCHWARTLA	ANDER, Bernhard		(b) (6) >; RYAN,
Michael J.	(b) (6) >; Pate	e Muhamed		(b) (6) Kanarek, Morg	gan
	1000	(b) (6)	(b) (6)	(b) (6)	
	(b) (6)				(b) (6); 'Sheila
Austria		(b) (6) >	; William Hall	(b) (6)	; Teresa Miller
de Vega		The state of the s	Marston Hilary	(b) (6)	>;
					(b) (6);
				(b) (6); Zacha	rie Gahungu

	(0) (0)
	name Pale
	oomas Palu
(b) (6) Subject: RE: GPMB: COVID-19 FUNDING NOTE	
Subject: RE. GPINIB. COVID-19 FONDING NOTE	
Dear Board Members,	
Ahead of the GPMB Board call on Wednesday, I'm pleased to attach a note Victor Dzau and a small working group) setting out the urgent need for new COVID-19 response.	**************************************
You will have seen the strong announcement today from the World Bank o country response, which we warmly welcome. We are asking for your feed	
	(b) (4
We look forward to the discussion.	
With best wishes,	
Alex	
Alex Harris	
Head of Global Policy & Advocacy	
Wellcome	
T: (b) (6)	
(b) (6)	

Help save paper! Do you really need to print this email?

Dit bericht kan informatie bevatten die niet voor u is bestemd. Indien u niet de geadresseerde bent of dit bericht abusievelijk aan u is toegezonden, wordt u verzocht dat aan de afzender te melden en het bericht te verwijderen. De Staat aanvaardt geen aansprakelijkheid voor schade, van welke aard ook, die verband houdt met risico's verbonden aan het elektronisch verzenden van berichten.

This message may contain information that is not intended for you. If you are not the addressee or if this message was sent to you by mistake, you are requested to inform the sender and delete the message. The State accepts no liability for damage of any kind resulting from the risks inherent in the electronic transmission of messages.

Sent: Sun, 1 Mar 2020 14:37:48 +0000 **To:** Fauci, Anthony (NIH/NIAID) [E]

Subject: Phone call

Sorry just not possible Saturday.

I can phone you any time after 2pm EST if you have 10 mins!

Wellcome exists to improve health by helping great ideas to thrive. We support researchers, we take on big health challenges, we campaign for better science, and we help everyone get involved with science and health research. We are a politically and financially independent foundation.

Sent: Wed, 26 Feb 2020 13:04:13 +0000

To: Barasch, Kimberly (NIH/NIAID) [C];Teresa Miller de Vega;Fauci, Anthony

(NIH/NIAID) [E]

Subject: Re: Can I give you a ring today

Thanks Kim!

From: "Barasch, Kimberly (NIH/NIAID) [C]" (b) (6)

Date: Wednesday, 26 February 2020 at 13:03

To: Teresa de Vega < (b) (6)

Cc: Jeremy Farrar (b) (6)

Subject: RE: Can | give you a ring today

Hi Teresa,

17:30 UK / 13:30 DC time on Thursday, 27 February will work well.

Thank you,

Kim

Kim Barasch [c]

Office of the Director

National Institute of Allergy & Infectious Diseases

(b) (6) (b) (6)

From: Teresa Miller de Vega (b) (6)

Sent: Wednesday, February 26, 2020 7:59 AM

To: Barasch, Kimberly (NIH/NIAID) [C] (b) (6)

Cc: Jeremy Farrar (b) (6)

Subject: RE: Can I give you a ring today

Hi Kim,

Jeremy will be able to call Tony after 17:30 UK / 13:30 DC time.

I hope this works.

Thank you,

Teresa

From: Jeremy Farrar (b) (6)

Sent: 26 February 2020 12:55

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6): Teresa Miller de Vega Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6) Barasch, Kimberly (NIH/NIAID) [C] Subject: Re: Can I give you a ring today Thanks Tony (b) (6)> From: "Fauci, Anthony (NIH/NIAID) [E]" Date: Wednesday, 26 February 2020 at 12:52 (b) (6) To: Jeremy Farrar Cc: "Conrad, Patricia (NIH/NIAID) [E]" (b) (6) "Barasch, Kimberly (b) (6) (NIH/NIAID) [C]" Subject: RE: Can | give you a ring today Thursday would be better. Any time between 11:00 AM and 4:00 PM DC time. (b) (6) and Kim will pull me out of any meeting I am Call my office at in. Anthony S. Fauci, MD Director National Institute of Allergy and Infectious Diseases Building 31, Room 7A-03 31 Center Drive, MSC 2520 **National Institutes of Health** Bethesda, MD 20892-2520 Phone: (FAX: (301) 496-4409 (b) (6) E-mail: The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives. (b) (6) From: Jeremy Farrar Sent: Wednesday, February 26, 2020 7:47 AM To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) Subject: Re: Can I give you a ring today I can much later at night (anytime up to midnight UK time) here Tony if that helps.....or Thursday also ok, if that is better for you?

From: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)

Date: Wednesday, 26 February 2020 at 12:45

To: Jeremy Farrar (b) (6)

Subject: RE: Can | give you a ring today

Unfortunately, I will be in the middle of a Congressional Hearing with Secretary Azar at 4:00 PM DC time. Any possibility for 1:00 PM DC time?

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone:
(b) (6)
FAX: (301) 496-4409

(b) (6)

E-mail:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jeremy Farrar (b) (6)

Sent: Wednesday, February 26, 2020 7:40 AM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)

Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6) >; Barasch, Kimberly (NIH/NIAID) [C]

(b) (6)

Subject: Re: Can I give you a ring today

Thanks Tony as always.....does something like 9pm UK time (4pm EST) work for you?

From: "Fauci, Anthony (NIH/NIAID) [E]"

Date: Wednesday, 26 February 2020 at 12:39

To: Jeremy Farrar

(b) (6)

Cc: "Conrad, Patricia (NIH/NIAID) [E]"

(NIH/NIAID) [C]"

(b) (6)

Subject: RE: Can | give you a ring today

Of course. I will be in and out of meetings, but call my office at 60 60

My staff will find me. If that does not work use my cell phone at 60 60

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (6) (6)

FAX: (301) 496-4409

E-mail: (b) (6) v

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jeremy Farrar (b) (6)
Sent: Wednesday, February 26, 2020 7:36 AM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)

Subject: Can | give you a ring today

Tony – Can I give you a ring anytime this evening UK time – can be late and fit in with you. Jeremy

Wellcome exists to improve health by helping great ideas to thrive. We support researchers, we take on big health challenges, we campaign for better science, and we help everyone get involved with science and health research. We are a politically and financially independent foundation.

Sent: Mon, 10 Feb 2020 09:26:57 +0000

To: M.P.G. Koopmans;Kristian G. Andersen;Drosten, Christian;Edward

Holmes; Andrew Rambaut; (b) (6); R.A.M. Fouchier; (b) (6); Collins,

Francis (NIH/OD) [E];Fauci, Anthony (NIH/NIAID) [E];Josie Golding;Mike Ferguson

Subject: Re: [ext] 2019 N-CoV

Many thanks all


Sydney had a complete power cut over the weekend which has delayed things a little.

(b) (5)

From: Marion Koopmans (b) (6)

Date: Sunday, 9 February 2020 at 20:07

To: "Kristian G. Andersen" (b) (6), "Drosten, Christian"



Subject: Re: [ext] 2019 N-CoV

Wow....took off from e-mail for a day.....

(b) (5)

		(1
Marion		
THUI TO THE TENT OF THE TENT O		
On 8 Feb 2020, at 22:15, Kristian G. Andersen	(b) (6) > wrote:	
Best, Kristian		
On Sat, Feb 8, 2020 at 12:38 PM Drosten, Christian OK, I see. Else it reads a bit funny.	(b) (б) > wrote:	(b) (5)

Christian

__

Professor Christian Drosten

Director, Institute of Virology Scientific Director, Charité Global Health

Charité - Universitätsmedizin Berlin

Campus Charité Mitte

Chariteplatz 1 D-10117 Berlin Germany


	(b) (6)
-	(b) (6

Von: Jeremy Farrar	(b) (6)	
Datum: Samstag, 8. Februar 20	20 um 21:21	
An: Edward Holmes	(b) (6), Christian Drosten	
(b) (6)		
Cc:	(b) (6) Andrew Rambaut	(b) (6) >,
	(b) (6)	2
		(b) (6)
,		(b) (6)
(b) (б), Josie G	olding (b) (6)	***
	(b)(6)>, Mike Ferguso	on
(b) (6		
Betreff: Re: [ext] 2019 N-CoV		


(b) (5)

From: Edward Holmes		(b) (6)	
Date: Saturday, 8 February 2			
To: Christian Drosten) (6)	***
Cc: Jeremy Farrar	(b) (6),		(b) (6)
	(b) (6)		(b) (6)
		(b) (6) "	(b) (6)
	, Francis Collins	(b) (6)	
		sie Golding	(b) (6) _,
Marion Koopmans		Mike Ferguson	
) (6)		
Subject: Re: [ext] 2019 N-Co\	1		
Hi Christian,			
			(b) (5
Best wishes,			
STOCKED CONTRACTOR CONTRACTOR OF CONTRACTOR			
Eddie			
PROFESSOR EDWARD C. HOI	MES FAA FRS		
ARC Australian Laureate Fellow			
THE UNIVERSITY OF SYDNEY			
Marie Bashir Institute for Infectiou	s Diseases & Biosecurity,		
School of Life & Environmental Sc	iences and School of Med	ical Sciences,	
The University of Sydney Sydney	NSW 2006 Australia		
T (b) (6)	10 - 10		
E (b) (6)			

(b) (6) wrote: On 9 Feb 2020, at 6:52 am, Drosten, Christian Dear All, I am overloaded with nCoV patient-related work and will need a few days before I can work on this text. (b)(5)Christian **Professor Christian Drosten** Director, Institute of Virology Scientific Director, Charité Global Health Charité - Universitätsmedizin Berlin Campus Charité Mitte Chariteplatz 1 D-10117 Berlin Germany E-Mail: (b) (6)




(b) (6)





These and other thoughts welcome in confidence.

Sent: To:		IIAID) [E]	
To:	Sat, 8 Feb 2020 17:36:3		
	그는 그리는 그리는 아이들이 살아왔다. 그 아이들이 아이들이 아이들이 아이들이 아니는 것이 없어요?	e, Patrick (GO-Science);Edward	
Holmes	(b) (6);Andrew Rambaut		
Cc:) (ର);Collins, Francis (NIH/OD) [E];Josie	
	(b) (6)	6) (6);Mike Ferguson;Government Ch	hief
Scientific Adviser (GO			
Subject:	RE: 2019 N-CoV		
			(b)
		E	
From: Jeremy Farrar	(b) (6)	0>	
Sent: Saturday, Febru	ary 8, 2020 10:13 AM		
To: Vallance, Patrick (GO-Science)	(b) (6); Edward Holmes	
	(b) (6);	(b) (6); Andrew Rambaut (b) ((6)
(b) (б)			
Cc:	(b) (6); Collins, Francis ((NIH/OD) [E] (b) (6); Fauci, Anthony	
(NIH/NIAID) [E]	(b) (6) Josie G		
AND COMMAND AND AND COMMAND AND SPECIAL	(b) (6)	(b) (6); Mike Ferguson	
	The state of the s	Chief Scientific Adviser (GO-Science) < GCSA@go-	
science.gov.uk>	A SECONDINION		
Subject: Re: 2019 N-C	oV		
Subject Ne. 2015 N e	••		
			,
Francis III (all and a 2)	wint (CO Coince All	42/6	
From: "Vallance, Pa		(b) (6)	
Date: Saturday, 8 Fe	ebruary 2020 at 12:03		
	ebruary 2020 at 12:03	(b) (6)	
Date: Saturday, 8 Fe	ebruary 2020 at 12:03		
Date: Saturday, 8 Fe	ebruary 2020 at 12:03 (b) (6)	(6) >, Edward Holmes (b) (6)	9 (6)



(b) (5)



These and other thoughts welcome in confidence.

Sent: Fri, 7 Feb 2020 18:54:20 +0000

To: Collins, Francis (NIH/OD) [E]; Fauci, Anthony (NIH/NIAID) [E]

Cc: Tabak, Lawrence (NIH/OD) [E]

Subject: Re: Revised draft

I do not think so yet but ...chasing!

From: Francis Collins (b) (6)

Date: Friday, 7 February 2020 at 12:17

To: Jeremy Farrar (b) (6), "Fauci, Anthony (NIH/NIAID) [E]"

(b) (6)

Cc: "Tabak, Lawrence (NIH/OD) [E]" (b) (6)

Subject: RE: Revised draft

(b) (5)

Francis

From: Jeremy Farrar (b) (6)

Sent: Friday, February 7, 2020 1:21 AM

To: Collins, Francis (NIH/OD) [E] (b) (6); Fauci, Anthony (NIH/NIAID) [E]

(b) (6)

Subject: Re: Revised draft

(b) (5)

Sent: Fri, 7 Feb 2020 15:05:56 +0000

To: Victor Dzau; Fauci, Anthony (NIH/NIAID) [E]; Vallance, Patrick (GO-Science)

Subject: Phone call

Victor

Let me know if a call on this would help, with either Tony, Patrick or I

https://abcnews.go.com/Politics/white-house-asks-scientists-investigate-origins-coronavirus/story?id=68807304

Tony (Francis), Patrick, myself and a close knit group have been looking at this for the last 10 days and might have some information to share which might help.

Best wishes Jeremy

Wellcome exists to improve health by helping great ideas to thrive. We support researchers, we take on big health challenges, we campaign for better science, and we help everyone get involved with science and health research. We are a politically and financially independent foundation.

Sent: Fri, 7 Feb 2020 06:09:31 +0000

To: Collins, Francis (NIH/OD) [E]; Fauci, Anthony (NIH/NIAID) [E]

Subject: Revised draft

Attachments: Summary.Feb7.pdf

Wellcome exists to improve health by helping great ideas to thrive. We support researchers, we take on big health challenges, we campaign for better science, and we help everyone get involved with science and health research. We are a politically and financially independent foundation.

Sent: Thu, 6 Feb 2020 07:18:09 +0000

To: Fauci, Anthony (NIH/NIAID) [E];Collins, Francis (NIH/OD) [E]

Cc: Josie Golding; Tabak, Lawrence (NIH/OD) [E]

Subject: Re: Prevalence of infection and stage of the epidemic in Wuhan

Perfect, thank you

From: "Fauci, Anthony (NIH/NIAID) [E]" <a (b) (6) >

Date: Wednesday, 5 February 2020 at 22:24

To: Jeremy Farrar (b) (6) Francis Collins (b) (6)

Cc: Josie Golding (b) (6), "Tabak, Lawrence (NIH/OD) [E]"

Subject: RE: Prevalence of infection and stage of the epidemic in Wuhan

Jeremy:

Thanks for the note. Looks like things are moving along with WHO. I will list below a number of names for potential members of the working group to examine the evolutionary origin of the 2019-nCoV in addition to the individuals who were on the call with us last Saturday:

Harold Varmus – Weill Cornell Medical Center – New York City

Feng Zhang – MIT (CRISPR expert)

Joseph DeRisi - Chan Zuckerberg (CZ) BioHub (he's paying close attention to the Wuhan strain vs other bat viruses and the SARS virus)

Don Ganem - University of California at San Francisco (UCSF) and the CZ BioHub (knows more about hepadnaviruses but an outstanding clinical and basic virologist)

John Coffin - Tufts and National Cancer Institute, NIH (worked out the confusion over the alleged Chronic Fatigue Syndrome retrovirus that proved to be a xenotropic MLV)

Eugene Koonin - NCBI/National Libreary of Medicine, NIH;

https://www.ncbi.nlm.nih.gov/research/groups/koonin/)

Wayne Hendrickson – Columbia University and the New York Structural Biology Center Gary Nabel – Sanofi (Boston)

Best regards,

Tony

Anthony S. Fauci, MD Director National Institute of Allergy and Infectious Diseases Building 31, Room 7A-03 31 Center Drive, MSC 2520 National Institutes of Health Bethesda, MD 20892-2520 Phone: (b) (6) FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jeremy Farrar (b) (6)

Sent: Wednesday, February 5, 2020 6:21 AM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >; Collins, Francis (NIH/OD) [E]

Cc: Josie Golding (b) (6)

(b) (6)

Subject: Re: Prevalence of infection and stage of the epidemic in Wuhan

Francis and Tony

Couple of things:

- I spoke again with WHO this morning. I believe they have listened and acted. Let me know if you agree
 - At the WHO meeting next week they will set up the Group who will "look at the origins and evolution of 2019n-CoV"
 - They have asked for names to sit on that Group please do send any names
 - We can have a call this week with a core group of that to frame the work of the Group including – if you could join?
 - o I think this puts it under the umbrella of WHO, with action this week and into next
 - With names to be put forward into the Group from us and pressure on this group from your and our teams next week.
- The team will update the draft today and I will forward immediately they will add further comments on the glycans

Does that sound reasonable to you?

Jeremy

From: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)

Date: Tuesday, 4 February 2020 at 13:18

To: Francis Collins (b) (6), Jeremy Farrar (b) (6)

Subject: RE: Prevalence of infection and stage of the epidemic in Wuhan

?? (6) (4)

Anthony S. Fauci, MD Director National Institute of Allergy and Infectious Diseases Building 31, Room 7A-03 31 Center Drive, MSC 2520 National Institutes of Health Bethesda, MD 20892-2520 Phone: (FAX: (301) 496-4409 (b) (6) E-mail: The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives. (b) (6) From: Collins, Francis (NIH/OD) [E] Sent: Tuesday, February 4, 2020 6:12 AM

Subject: Re: Prevalence of infection and stage of the epidemic in Wuhan

(b) (4)

On 4 Feb 2020, at 10:58, Collins, Francis (NIH/OD) [E] (b) (6) wrote:

Francis

From: Jeremy Farrar (b) (6

Sent: Tuesday, February 4, 2020 2:01 AM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Collins, Francis (NIH/OD) [E]

(b) (6)

Subject: FW: Prevalence of infection and stage of the epidemic in Wuhan

Please treat in confidence – a very rough first draft from Eddie and team – they will send on the edited, cleaner version later.

Pushing WHO again today

From: Edward Holmes (b) (6)

Date: Tuesday, 4 February 2020 at 06:33

To: Jeremy Farrar (b) (6)

Subject: Re: Prevalence of infection and stage of the epidemic in Wuhan

Here's our summary so far. Will be edited further.

It's fundamental science and completely neutral as written. Did not mention other anomalies as this will make us look like loons. As it stands it is excellent basic science I think, which is a service in itself.

Will finish as soon as we can.

PROFESSOR EDWARD C. HOLMES FAA FRS

ARC Australian Laureate Fellow

THE UNIVERSITY OF SYDNEY

Marie Bashir Institute for Infectious Diseases & Biosecurity,

School of Life & Environmental Sciences and School of Medical Sciences,

The University of Sydney | Sydney | NSW | 2006 | Australia

T (b) (6)

E (b) (6)

Sent: Thu, 6 Feb 2020 07:17:40 +0000

To: Fauci, Anthony (NIH/NIAID) [E];Collins, Francis (NIH/OD) [E]

Cc: Josie Golding; Tabak, Lawrence (NIH/OD) [E]

Subject: Re: Prevalence of infection and stage of the epidemic in Wuhan

Thank you. Pardis is great, respected by everyone – best wishes Jeremy

From: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)

Date: Thursday, 6 February 2020 at 00:00

To: Jeremy Farrar (b) (6), Francis Collins (b) (6)

Cc: Josie Golding (b) (6), "Tabak, Lawrence (NIH/OD) [E]"

Subject: RE: Prevalence of infection and stage of the epidemic in Wuhan

Jeremy:

I left out an important name for the coronavirus evolution working group. Please include her: Pardis Sabeti at the Broad Institute of MIT and Harvard Thanks,

Tony

Anthony S. Fauci, MD

Director

National Institute of Allergy and Infectious Diseases

Building 31, Room 7A-03 31 Center Drive, MSC 2520 National Institutes of Health Bethesda, MD 20892-2520 Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]

Sent: Wednesday, February 5, 2020 5:25 PM

To: Jeremy Farrar (b) (6); Collins, Francis (NIH/OD) [E] (b) (6)

Cc: Josie Golding (b) (6); Tabak, Lawrence (NIH/OD) [E]

(b) (6)

Subject: RE: Prevalence of infection and stage of the epidemic in Wuhan

Jeremy:

Thanks for the note. Looks like things are moving along with WHO. I will list below a number of names for potential members of the working group to examine the evolutionary origin of the 2019-nCoV in addition to the individuals who were on the call with us last Saturday:

Harold Varmus – Weill Cornell Medical Center – New York City

Feng Zhang – MIT (CRISPR expert)

Joseph DeRisi - Chan Zuckerberg (CZ) BioHub (he's paying close attention to the Wuhan strain vs other bat viruses and the SARS virus)

Don Ganem - University of California at San Francisco (UCSF) and the CZ BioHub (knows more about hepadnaviruses but an outstanding clinical and basic virologist)

John Coffin - Tufts and National Cancer Institute, NIH (worked out the confusion over the alleged Chronic Fatigue Syndrome retrovirus that proved to be a xenotropic MLV)

Eugene Koonin - NCBI/National Libreary of Medicine, NIH;

https://www.ncbi.nlm.nih.gov/research/groups/koonin/)

Wayne Hendrickson – Columbia University and the New York Structural Biology Center Gary Nabel – Sanofi (Boston)

Best regards, Tony

E-mail:

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (6) (6)
FAX: (301) 496-4409

(b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jeremy Farrar (b) (6)

Sent: Wednesday, February 5, 2020 6:21 AM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Collins, Francis (NIH/OD) [E]

(b) (6)

Cc: Josie Golding (b) (6)

Subject: Re: Prevalence of infection and stage of the epidemic in Wuhan

Francis and Tony

Couple of things:

- I spoke again with WHO this morning. I believe they have listened and acted. Let me know if you agree
 - At the WHO meeting next week they will set up the Group who will "look at the origins and evolution of 2019n-CoV"
 - They have asked for names to sit on that Group please do send any names
 - We can have a call this week with a core group of that to frame the work of the Group including – if you could join?
 - o I think this puts it under the umbrella of WHO, with action this week and into next
 - With names to be put forward into the Group from us and pressure on this group from your and our teams next week.
- The team will update the draft today and I will forward immediately they will add further comments on the glycans

Does that sound reasonable to you?

Jeremy

From: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)

Date: Tuesday, 4 February 2020 at 13:18

To: Francis Collins (b) (6), Jeremy Farrar (b) (6)

Subject: RE: Prevalence of infection and stage of the epidemic in Wuhan

??

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone:
(b) (6)
FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Collins, Francis (NIH/OD) [E]	(b) (6)	
Sent: Tuesday, February 4, 2020 6:12 AM		
1435-1430-143-1430-1430-1430-1430-1430-1430-)(6)	
Cc: Fauci, Anthony (NIH/NIAID) [E]	(b) (6)	
Subject: RE: Prevalence of infection and sta	age of the epidemic in Wuhan	
Yes,	(b) (4)	
Francis		
From: Jeremy Farrar	(b) (6)	
Sent: Tuesday, February 4, 2020 6:08 AM	4)(0)	
To: Collins, Francis (NIH/OD) [E]	(b) (6) (b) (6)	
Cc: Fauci, Anthony (NIH/NIAID) [E] Subject: Re: Prevalence of infection and sta	The second secon	
Subject. Re. Frevalence of infection and sta	age of the epidentic in wurlan	
		(b) (4)
On 4 Feb 2020, at 10:58, Collins, Francis (N	IIH/OD) [E] < (b) (6) > wrote:	
A.C		(b) (4)
Verv thoughtful analysis.		(b) (4)
F1		
Francis		
· .		
	(6) (6) >	
Sent: Tuesday, February 4, 2020 2:01 AM	(b) (C) Calling Francis (NULL/OD) [5]	
To: Fauci, Anthony (NIH/NIAID) [E] <	(b) (6)>; Collins, Francis (NIH/OD) [E]	
Subject: FW: Prevalence of infection and st	tage of the epidemic in Wuhan	
and an area of the		
Please treat in confidence – a very rough fi	irst draft from Eddie and team – they will send on the edited,	
cleaner version later.	72	
Pushing WHO again today		

From: Edward Holmes (b) (6)

Date: Tuesday, 4 February 2020 at 06:33 **To:** Jeremy Farrar (b) (6)

Subject: Re: Prevalence of infection and stage of the epidemic in Wuhan

Here's our summary so far. Will be edited further.

It's fundamental science and completely neutral as written. Did not mention other anomalies as this will make us look like loons. As it stands it is excellent basic science I think, which is a service in itself.

Will finish as soon as we can.

.....

PROFESSOR EDWARD C. HOLMES FAA FRS

ARC Australian Laureate Fellow

THE UNIVERSITY OF SYDNEY

Marie Bashir Institute for Infectious Diseases & Biosecurity, School of Life & Environmental Sciences and School of Medical Sciences, The University of Sydney | Sydney | NSW | 2006 | Australia

T (b) (6) (b) (6)

Sent: Wed, 5 Feb 2020 06:57:54 +0000

To: Collins, Francis (NIH/OD) [E]; Fauci, Anthony (NIH/NIAID) [E]; Edward Holmes

Subject: FW: Origins Attachments: Summary.pdf

Tony and Francis

The revised draft from Eddie, copied here.



4 pages Withheld in Full Pursuant to FOIA Exemption (b)(5) immediately following this page

Sent: Tue, 4 Feb 2020 20:53:09 +0000

To: Collins, Francis (NIH/OD) [E]; Fauci, Anthony (NIH/NIAID) [E]

Subject: Origins

Attachments: Summary.pdf

Tidied up

Wellcome exists to improve health by helping great ideas to thrive. We support researchers, we take on big health challenges, we campaign for better science, and we help everyone get involved with science and health research. We are a politically and financially independent foundation.

The Wellcome Trust is a charity registered in England and Wales, no. 210183. Its sole trustee is The Wellcome Trust Limited, a company registered in England and Wales, no. 2711000 (whose registered office is at 215 Euston Road, London NW1 2BE, UK)

Sent: Tue, 4 Feb 2020 20:26:23 +0000

To: Collins, Francis (NIH/OD) [E]; Fauci, Anthony (NIH/NIAID) [E]

Subject: Re: Prevalence of infection and stage of the epidemic in Wuhan

Wild West.....

From: Francis Collins (b) (6)

Date: Tuesday, 4 February 2020 at 20:23

To: Jeremy Farrar (b) (6), "Fauci, Anthony (NIH/NIAID) [E]"

(b) (6)

Subject: RE: Prevalence of infection and stage of the epidemic in Wuhan

From: Jeremy Farrar (b) (6)
Sent: Tuesday, February 4, 2020 9:03 AM

To: Fauci, Anthony (NIH/NIAID) [E] < (b) (6) Collins, Francis (NIH/OD) [E]

(b)(5)

(b) (6)

Subject: Re: Prevalence of infection and stage of the epidemic in Wuhan

Exactly!

From: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6) >

Date: Tuesday, 4 February 2020 at 13:18

To: Francis Collins (b) (6), Jeremy Farrar < (b) (6)

Subject: RE: Prevalence of infection and stage of the epidemic in Wuhan

?? (b) (4)

Anthony S. Fauci, MD

Director

National Institute of Allergy and Infectious Diseases

Building 31, Room 7A-03 31 Center Drive, MSC 2520 National Institutes of Health Bethesda, MD 20892-2520 Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Collins, Francis (NIH/OD) [E] (b) (6) Sont: Tuesday, February 4, 2020 6:12 AM	
Sent: Tuesday, February 4, 2020 6:12 AM To: Jeremy Farrar (b) (6)	
Cc: Fauci, Anthony (NIH/NIAID) [E] (b) (6)	
Subject: RE: Prevalence of infection and stage of the epidemic in Wuhan	
Yes, (b) (4)	
Francis	
From: Jeremy Farrar (b) (6) Sent: Tuesday, February 4, 2020 6:08 AM To: Collins, Francis (NIH/OD) [E] (b) (6) Cc: Fauci, Anthony (NIH/NIAID) [E] (b) (6) Subject: Re: Prevalence of infection and stage of the epidemic in Wuhan	
Subject. No. 17 evalence of infection and stage of the optioning in violating	(b) (4)
On 4 Feb 2020, at 10:58, Collins, Francis (NIH/OD) [E] (b) (6) wrote:	
Very thoughtful analysis.	(b) (4) (b)
Francis	
From: Jeremy Farrar (b) (6) Sent: Tuesday, February 4, 2020 2:01 AM To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >; Collins, Francis (NIH/OD) [E]	
Subject: FW: Prevalence of infection and stage of the epidemic in Wuhan	
Please treat in confidence – a very rough first draft from Eddie and team – they will send on the edited, cleaner version later.	
Pushing WHO again today	

From: Edward Holmes (b) (6)

Date: Tuesday, 4 February 2020 at 06:33 **To:** Jeremy Farrar (b) (6)

Subject: Re: Prevalence of infection and stage of the epidemic in Wuhan

Here's our summary so far. Will be edited further.

It's fundamental science and completely neutral as written. Did not mention other anomalies as this will make us look like loons. As it stands it is excellent basic science I think, which is a service in itself.

Will finish as soon as we can.

.....

PROFESSOR EDWARD C. HOLMES FAA FRS

ARC Australian Laureate Fellow

THE UNIVERSITY OF SYDNEY

Marie Bashir Institute for Infectious Diseases & Biosecurity, School of Life & Environmental Sciences and School of Medical Sciences, The University of Sydney | Sydney | NSW | 2006 | Australia

T (b) (6) (b) (6)

the convening started.	ummary and analysis.	We really need to get WHO moving	on getting
From: Collins, Francis (NIH/ Sent: Tuesday, February 4,		(b) (6)	
To: Jeremy Farrar	(b) (6)		
Cc : Fauci, Anthony (NIH/NIA Subject: RE: Prevalence of i		(b) (6) e epidemic in Wuhan	
Yes,		600	(b) (4)
Francis			
	42/0		
From: Jeremy Farrar Sent: Tuesday, February 4, To: Collins, Francis (NIH/OD		o) (6)	
Cc: Fauci, Anthony (NIH/NIA Subject: Re: Prevalence of i	AID) [E]	(b) (6)	
^	1097		(b)
On 4 Feb 2020, at 10:58, Co	llins, Francis (NIH/OD) [E] (b) (6) wrote:	
Very thoughtful analysis.			(b) (4
,			(b)

Fauci, Anthony (NIH/NIAID) [E]

Tue, 4 Feb 2020 11:23:44 +0000

Collins, Francis (NIH/OD) [E];Jeremy Farrar

From:

Sent:

To:

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Collins, Francis (NIH/OD) [E]

Subject: FW: Prevalence of infection and stage of the epidemic in Wuhan

Please treat in confidence - a very rough first draft from Eddie and team - they will send on the edited, cleaner version later.

Pushing WHO again today

From: Edward Holmes (b) (6)

Date: Tuesday, 4 February 2020 at 06:33 To: Jeremy Farrar

Subject: Re: Prevalence of infection and stage of the epidemic in Wuhan

Here's our summary so far. Will be edited further.

It's fundamental science and completely neutral as written. Did not mention other anomalies as this will make us look like loons. As it stands it is excellent basic science I think, which is a service in itself.

Will finish as soon as we can.

PROFESSOR EDWARD C. HOLMES FAA FRS

ARC Australian Laureate Fellow

THE UNIVERSITY OF SYDNEY

Marie Bashir Institute for Infectious Diseases & Biosecurity, School of Life & Environmental Sciences and School of Medical Sciences, The University of Sydney | Sydney | NSW | 2006 | Australia

E (b) (6)

Sent: Tue, 4 Feb 2020 07:01:16 +0000

To: Fauci, Anthony (NIH/NIAID) [E];Collins, Francis (NIH/OD) [E]

Subject: FW: Prevalence of infection and stage of the epidemic in Wuhan

Attachments: Summary.docx

Please treat in confidence – a very rough first draft from Eddie and team – they will send on the edited, cleaner version later.

Pushing WHO again today

From: Edward Holmes (b) (6)

Date: Tuesday, 4 February 2020 at 06:33 **To:** Jeremy Farrar (b) (6)

Subject: Re: Prevalence of infection and stage of the epidemic in Wuhan

Here's our summary so far. Will be edited further.

It's fundamental science and completely neutral as written. Did not mention other anomalies as this will make us look like loons. As it stands it is excellent basic science I think, which is a service in itself.

Will finish as soon as we can.

PROFESSOR EDWARD C. HOLMES FAA FRS

ARC Australian Laureate Fellow

THE UNIVERSITY OF SYDNEY

Marie Bashir Institute for Infectious Diseases & Biosecurity, School of Life & Environmental Sciences and School of Medical Sciences, The University of Sydney | Sydney | NSW | 2006 | Australia

T (b) (6) (b) (6)

Sent: Sun, 2 Feb 2020 17:47:36 +0000

To: Michael RYAN;Bernhard Schwartländer;Collins, Francis (NIH/OD) [E];Fauci,

Anthony (NIH/NIAID) [E];Dr Tedros **Subject:** 2019nC-V

Mike and Bernhard

Thank you for phoning – very helpful, copying in Francis and Tony as well as Tedros.

Fully agree with your summary.



Hope that is a reasonable summary

Wellcome exists to improve health by helping great ideas to thrive. We support researchers, we take on big health challenges, we campaign for better science, and we help everyone get involved with science and health research. We are a politically and financially independent foundation.

The Wellcome Trust is a charity registered in England and Wales, no. 210183. Its sole trustee is The Wellcome Trust Limited, a company registered in England and Wales, no. 2711000 (whose registered office is at 215 Euston Road, London NW1 2BE, UK)

Sent: Sun, 2 Feb 2020 16:28:29 +0000

To: Fauci, Anthony (NIH/NIAID) [E];Collins, Francis (NIH/OD) [E]

Cc: Tabak, Lawrence (NIH/OD) [E]

....Really appreciate us thinking through the options.....

Subject: Re: Teleconference

Tedros and Bernhard have apparently gone into conclave....they need to decide today in my view. If they do prevaricate, I would appreciate a call with you later tonight or tomorrow to think how we might take forward.

Meanwhile....

https://www.zerohedge.com/geopolitical/coronavirus-contains-hiv-insertions-stoking-fears-over-artificially-created-bioweapon

(b) (6) From: "Fauci, Anthony (NIH/NIAID) [E]" Date: Sunday, 2 February 2020 at 15:30 (b) (6), Francis Collins (b) (6) To: Jeremy Farrar (b) (6) Cc: "Tabak, Lawrence (NIH/OD) [E]" Subject: RE: Teleconference Jeremy: Sorry that I took so long to weigh in on your e-mails with Francis and me. I was on (b)(5)conference calls. (b)(5)Best regards, Tony From: Jeremy Farrar (b) (6) Sent: Sunday, February 2, 2020 7:13 AM To: Collins, Francis (NIH/OD) [E] (b) (6) Cc: Fauci, Anthony (NIH/NIAID) [E] (b) (6) Tabak, Lawrence (NIH/OD) [E] (b) (6) Subject: Re: Teleconference

(b) (5)

From: Francis Collins (b) (6) Date: Sunday, 2 February 2020 at 12:03	
To: Jeremy Farrar (b) (6)	
Cc: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6), "Tabak, Lawrence (NIH/OD) [E]" (b) (6)	
Subject: RE: Teleconference	
Hi Jeremy,	
Thanks for forwarding these additional reflections from Mike and Bob.	(b) (5) (b) (5)
Francis	
From: Jeremy Farrar (b) (6) Sent: Sunday, February 2, 2020 6:53 AM To: Collins, Francis (NIH/OD) [E] (b) (6) Cc: Fauci, Anthony (NIH/NIAID) [E] (b) (6) Tabak, Lawrence (NIH/OD) [E]	
(b) (6) Subject: Re: Teleconference	
Thank you	
See thoughts overnight from others.	0.76
	(b) (5
Jeremy	
	(b) (5)

(Б) (5)

From: Francis Collins (b) (6) > Date: Sunday, 2 February 2020 at 10:27

To: Jeremy Farrar (b) (6)

Cc: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6) "Tabak, Lawrence (NIH/OD) [E]"

(b) (6) **Subject:** RE: Teleconference Jeremy,

(b) (5)

I'm available any time today except 3:15 - 5:45 pm EST (on a plane) for a call to Tedros. Let me know if I can help get through his thicket of protectors.

Francis

(b) (6) From: Jeremy Farrar Sent: Sunday, February 2, 2020 4:48 AM To: Andrew Rambaut (b) (6) (b) (6); Fauci, Anthony (NIH/NIAID) [E] Cc: R.A.M. Fouchier (b) (6); Drosten, Christian (b) (6) >; Patrick Vallance (b) (6); M.P.G. Koopmans (b) (6); Eddie Holmes (b) (6); (b) (6); Kristian G. Andersen Paul Schreier (b) (6) (b) (6); Ferguson, Mike (b) (6); Collins, Francis (NIH/OD) [E] (b) (6); Tabak, Lawrence (NIH/OD) [E] (b) (6); Josie Golding (b) (6) Subject: Re: Teleconference

This is a very complex issue.

I will:



I suggest we don't get into a further scientific discussion here, but wait for that group to be established.

Jeremy

From:			(b) (6)				
Date: Sunday, 2 Fe	bruary 2020 a	t 09:38					
To: Jeremy Farrar		(b	(6)				
Cc:	(b) (6)			(b) (6), "Fa	auci, An	thon	y (NIH/NIAID) [E]"
	(b) (6), Patrick \	/allance			(b) (6)	"Drosten,
Christian"		(b) (6)	Marion Koo	pmans			(b) (6)
Edward Holmes			(b) (6)		(Ь)) (6) "	
	(b) (6), "Kristian	G. Ander	sen"		(b) (6)	, Paul	Schreier
	(b) (6)		(b) (6) "			(b) (6)	Michael FMedSci
	(b) (6)	, Francis C	ollins		(b) (6)		
			(b) (6	Josie Go	Iding		
	(b) (6) >		*				
	COLUMN TO THE PROPERTY OF THE PARTY.						

Subject: Re: Teleconference

Dear Jeremey, Ron and all,

Thanks for inviting me on the call yesterday.


(b) (3)
(c) (7)

Best, Andrew

On 2 Feb 2020, at 08:40, Jeremy Farrar (b) (6) wrote:

Thanks Ron

	(b) (5)
Thoughts on that very welcome.	
On 2 Feb 2020, at 08:30, R.A.M. Fouchier (b) (6) wrote: Dear Jeremy and others, This was a very useful teleconference.	(b) (5) (b) (5)
Thanks for organizing this on such short notice, Kind regards Ron	
Ron's notes:	(6) (5)



	(t

Van: Jeremy Farrar (b) (6) Datum: zaterdag 1 februari 2020 om 21:59 Aan: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6) Patrick Vallance (b) (6) CC: Christian Drosten (b) (6), "M. Koopmans" (b) (6), "R.A.M. (b) (6) >, Edward (b) (6) (b) (6) Holmes (b) (6) (b) (6), "Kristian G. Andersen" Andrew Rambaut (b) (6), Paul (b) (6) Schreier (b) (6) (b) (6) (b) (6) Francis Collins "Ferguson, Mike" (b) (6) >, (b) (6) Josie Golding

Onderwerp: Re: Teleconference

Thank you to everyone for joining.

There is clearly much to understand understand in this. This call was very helpful to hear some of our current understanding and the many gaps in our knowledge.

(b) (5) (b) (5) I hope that is a reasonable approach, please send any thoughts or suggestions.

Once again, thank you for making time over a weekend and for such an informed discussion on a complex issue.

Thank you and best wishes Jeremy

From: Jeremy Fa	rrar		(b) (6)				
Date: Saturday,	1 Februa	ary 2020 at 15:34	1				
To: "Fauci, Antho	ony (NIF	I/NIAID) [E]"		(b) (6) _, Pa	trick Valla	ance	
		(b) (6)					
Cc: "Drosten, Christian"		(b)	(6) Marior	Koopma	ns		
		(b) (6) _,		(b) (6)			(b) (6)
Edward Holmes			(b) (6)	1762	(b)	(6)	
	(b) (6)		(b) (6) "		(b) (6)	'Kristian G.	Andersen"
	(b) (6)	Paul Schreier			(b) (6)		(b) (6) "
	(b) (6), p	Michael FMedSci			(b) (6)		

Subject: Teleconference

1st February (2nd Feb for Eddie)

Information and discussion is shared in total confidence and not to be shared until agreement on next steps.

Dial in details attached.

Please mute phones.

I will be on email throughout - email Paul or I Paul if any problems

If you cannot make it, I will phone you afterwards to update.

One Hour

6am Sydney 8pm CET 7pm GMT 2pm EST 11am PST (Hope I have the times right!)

Thank you for the series of calls and for agreeing to join this call.

Agenda

- · Introduction, focus and desired outcomes JF
- Summary KA
- Comments EH
- Q&A All
- Summary and next steps JF

Kristian Anderson

Bob Garry - I have not been able to contact Bob. Please forward if you can.

Christian Drosten

Tony Fauci

Mike Ferguson

Ron Fouchier

Eddie Holmes

Marion Koopmans

Stefan Pohlmann

Andrew Rambaut

Paul Schreier

Patrick Vallance

Andrew Rambaut

Institute for Evolutionary Biology

Ashworth Laboratories, University of Edinburgh, Edinburgh, EH9 3FL, UK

contact - (b) (6) | http://tree.bio.ed.ac.uk | tel (b) (6)

The University of Edinburgh is a charitable body, registered in Scotland, with registration number SC005336.

From: Sent: To: Subject:	Fauci, Anthony (NIH/NIAID) [E] Sat, 1 Feb 2020 22:06:26 +0000 Jeremy Farrar; Collins, Francis (NIH/OD) [E] RE: Teleconference
Thanks, Jeremy. We Best, Tony	really appreciate what you are doing here. Pleasure to work with you.
From: Jeremy Farrar Sent: Saturday, Februa To: Collins, Francis (NIH Cc: Fauci, Anthony (NIH Subject: Re: Teleconfer We are altogether as you great working with you	(b) (6) (7) (B) (B) (B) (B) (B) (B) (B) (B) (B) (B
From: Francis Collins Date: Saturday, 1 Feb To: Jeremy Farrar Cc: "Fauci, Anthony (I Subject: Re: Teleconf	(b) (6) NIH/NIAID) [E]"
	able at any time 24/7 for the call with Tedros. Just let me know. ship on this critical and sensitive issue.
On Feb 1, 2020, at 3:07 I have rejoined so a line	PM, Jeremy Farrar (b) (6) wrote:
From: Jeremy Farrar Date: Saturday, 1 Feb.	

6) டு, Patrick Vallance

Subject: Re: Teleconference

(b) (6) Michael FMedSci

(b) (6)

Can I suggest we shut down the call and then redial in?

Just for 5-10mins?

The second process of the contract of the cont	From: Marion K	Coopmans		(b) (6)	
Cc: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6), Patrick Vallance (b) (6) r (b) (6), Edward Holmes (c) (b) (6), (b) (6) (b) (6) (d) (6) (7), Wristian G. Andersen" (b) (6), (b) (6), (b) (6), (b) (6), (b) (6), (b) (6), (c) Paul Schreier (b) (6), Francis Collins (b) (6), (b) (6), (c) (d)	Date: Saturday,	1 February 202	0 at 19:43		
(b)(6) >, "Drosten, Christian" (b)(6), (b)(6) r (b)(6), Edward Holmes (c) (d) (d) (d) (d) (d) (d) (d) (d) (d) (b)(6) (b)(6) (d)	To: Jeremy Farr	ar	(b) (6)		
(b) (6) r (b) (6) , Edward Holmes (b) (6) , (c) (d) (d) (d) (d) (d) (d) (d) (d) (d) (d	Cc: "Fauci, Anth	ony (NIH/NIAIE) [E]"	(b) (6), Patrick Valla	nce
(b)(6) (b)(6) (b)(6) (b)(6) (b)(6) (b)(6) (c)(6) (c)(6) (d)(6) (d)(6) (d)(6) (d)(6) (d)(6) (d)(6) (d)(6) (d)(6) (d)(6) (d)(6) (d)(7) (d)(7) (d)(8) (d)(7) (e)(9) (d)(7) (e)(1) (d)(1) (e)(2) (d)(1) (e)(3) (d)(1) (e)(3) (d)(1) (e)(3) (d)(1) (e)(3) (d)(1) (e)(4) (d)(1) (e)(5) (d)(1) (e)(6) (d)(1) (e)(7) (d)(1) (e)(8) (d)(1) (e)(9) (d)(1) (e)(1) (d)(1) (e)(1) (d)(1) (e)(1) (d)(1) (e)(2) (d)(1) (e)(2) (d)(1) (e)(2) (d)(1)		(b)	6, "Drosten, Chr	istian"	(b) (6) _,
" (b) (6) (b) (6) >, "Kristian G. Andersen" (b) (6), Paul Schreier (b) (6), (b) (6) (b) (6), Michael FMedSci (b) (6), Francis Collins (b) (6)		(b) (6) r		(b) (6), Edward Holmes	
Paul Schreier (b) (6), (b) (6), (b) (6), Michael FMedSci (b) (6), Francis Collins (b) (6)	<		b) (6),	(b) (6)	(b) (6)
Michael FMedSci (b) (6), Francis Collins (b) (6)	ii.	(b) (6)	(b) (6) >, "	Kristian G. Andersen"	(b) (6)
	Paul Schreier		(b) (6)	(b) (6)	(b) (6)
Subject: Re: Teleconference	Michael FMedS	ci	(b) (d), Francis Collins	(b) (6)
	Subject: Re: Tel	econference			
			_		

On 1 Feb 2020, at 19:12, Jeremy Farrar (b) (6) wrote:

Kristen and Eddie have shared this and will talk through it on the call. Thank you.

Hope it will help frame the discussions.

From: Jeremy Farrar (b) (6)

Date: Saturday, 1 February 2020 at 15:34

1st February (2nd Feb for Eddie)

Information and discussion is shared in total confidence and not to be shared until agreement on next steps.

Dial in details attached.

Please mute phones.

I will be on email throughout – email Paul or I Paul if any problems

If you cannot make it, I will phone you afterwards to update.

One Hour

6am Sydney 8pm CET 7pm GMT 2pm EST 11am PST (Hope I have the times right!)

Thank you for the series of calls and for agreeing to join this call.

Agenda

- · Introduction, focus and desired outcomes JF
- Summary KA
- Comments EH
- Q&A All
- Summary and next steps JF

Kristian Anderson

Bob Garry - I have not been able to contact Bob. Please forward if you can.

Christian Drosten

Tony Fauci

Mike Ferguson

Ron Fouchier

Eddie Holmes

Marion Koopmans

Stefan Pohlmann

Andrew Rambaut

Paul Schreier

Patrick Vallance

<Coronavirus sequence comparison[1].pdf>

Sent: Sat, 1 Feb 2020 20:13:15 +0000

To: Collins, Francis (NIH/OD) [E]; Fauci, Anthony (NIH/NIAID) [E]; Ferguson,

Mike; Patrick Vallance

Subject: Re: Teleconference

sure

From: Francis Collins (b) (6)

Date: Saturday, 1 February 2020 at 20:12

To: Jeremy Farrar (b) (6), "Fauci, Anthony (NIH/NIAID) [E]"

6) டு, Michael FMedSci 6) டு, Patrick Vallance

(b) (6)

Subject: RE: Teleconference

Just saw this, still want me to call in?

From: Jeremy Farrar (b) (6)

Sent: Saturday, February 1, 2020 2:56 PM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) Collins, Francis (NIH/OD) [E] (b) (6) ; Ferguson, Mike (b) (6) ; Patrick Vallance

(b) (6)

Subject: Re: Teleconference

Can I suggest we shut down the call and then redial in?

Just for 5-10mins?

From: Marion Koopmans (b) (6)

Date: Saturday, 1 February 2020 at 19:43 **To:** Jeremy Farrar

(b) (6)

Cc: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6) >, Patrick Vallance

(b) (6)

(b) (6), "Drosten, Christian" (b) (6)

(b) (6), Edward Holmes

(b) (6) (b) (6), "Kristian G. Andersen" (b) (6), Paul Schreier (b) (6) (b) (6) (b) (6)

(b) (6)

(b) (6)

Michael FMedSci (b) (6) Francis Collins (b) (6)

Subject: Re: Teleconference

(b) (5)

On 1 Feb 2020, at 19:12, Jeremy Farrar (b) (6) wrote:

Kristen and Eddie have shared this and will talk through it on the call. Thank you.

Hope it will help frame the discussions.

From: Jeremy Farrar (b) (6)

Date: Saturday, 1 February 2020 at 15:34

1st February (2nd Feb for Eddie)

Information and discussion is shared in total confidence and not to be shared until agreement on next steps.

Dial in details attached.

Please mute phones.

I will be on email throughout – email Paul or I Paul if any problems

If you cannot make it, I will phone you afterwards to update.

One Hour

6am Sydney 8pm CET 7pm GMT 2pm EST 11am PST (Hope I have the times right!)

Thank you for the series of calls and for agreeing to join this call.

Agenda

- Introduction, focus and desired outcomes JF
- Summary KA
- Comments EH
- Q&A All
- Summary and next steps JF

Kristian Anderson

Bob Garry - I have not been able to contact Bob. Please forward if you can.

Christian Drosten

Tony Fauci

Mike Ferguson

Ron Fouchier

Eddie Holmes

Marion Koopmans

Stefan Pohlmann

Andrew Rambaut

Paul Schreier

Patrick Vallance

<Coronavirus sequence comparison[1].pdf>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 1 Feb 2020 20:03:12 +0000

To: Jeremy Farrar
Subject: RE: Teleconference

Yes

From: Jeremy Farrar (b) (6) >

Sent: Saturday, February 1, 2020 2:56 PM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Collins, Francis (NIH/OD) [E] (b) (6); Ferguson, Mike (b) (6); Patrick Vallance (b) (6)

Subject: Re: Teleconference

Can I suggest we shut down the call and then redial in?


Just for 5-10mins?

From: Marion Koopmans (b) (6)

Date: Saturday, 1 February 2020 at 19:43 **To:** Jeremy Farrar

(b) (6)

Cc: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6) Patrick Vallance



Subject: Re: Teleconference

(b)(5)

On 1 Feb 2020, at 19:12, Jeremy Farrar (b) (6) wrote:

Kristen and Eddie have shared this and will talk through it on the call. Thank you.

Hope it will help frame the discussions.

From: Jeremy Farrar (b) (6)

Date: Saturday, 1 February 2020 at 15:34

1st February (2nd Feb for Eddie)

Information and discussion is shared in total confidence and not to be shared until agreement on next steps.

Dial in details attached.

Please mute phones.

I will be on email throughout – email Paul or I Paul if any problems

If you cannot make it, I will phone you afterwards to update.

One Hour

6am Sydney 8pm CET 7pm GMT 2pm EST 11am PST (Hope I have the times right!)

Thank you for the series of calls and for agreeing to join this call.

Agenda

- Introduction, focus and desired outcomes JF
- Summary KA
- Comments EH
- Q&A All
- Summary and next steps JF

Kristian Anderson

Bob Garry - I have not been able to contact Bob. Please forward if you can. Christian Drosten

Tony Fauci
Mike Ferguson
Ron Fouchier
Eddie Holmes
Marion Koopmans
Stefan Pohlmann
Andrew Rambaut
Paul Schreier
Patrick Vallance

<Coronavirus sequence comparison[1].pdf>

Sent: Sat, 1 Feb 2020 19:09:05 +0000

To: Fauci, Anthony (NIH/NIAID) [E]; Patrick Vallance

Cc: Drosten, Christian; Marion Koopmans; R.A.M. Fouchier; Edward


Holmes (b) (6); Andrew Rambaut; Kristian G. Andersen; Paul

Schreier (b) (6); Ferguson, Mike; Collins, Francis (NIH/OD) [E]; Tabak, Lawrence (NIH/OD)

[E];Josie Golding

Subject: Re: Teleconference

If any issues come up, please email me and I will try and adjust or try and help.



Subject: Teleconference

1st February (2nd Feb for Eddie)

Information and discussion is shared in total confidence and not to be shared until agreement on next steps.

Dial in details attached.

Please mute phones.

I will be on email throughout – email Paul or I Paul if any problems

If you cannot make it, I will phone you afterwards to update.

One Hour

6am Sydney

8pm CET

7pm GMT

2pm EST

11am PST

(Hope I have the times right!)

Thank you for the series of calls and for agreeing to join this call.

Agenda

- Introduction, focus and desired outcomes JF
- Summary KA
- Comments EH
- Q&A All
- Summary and next steps JF

Kristian Anderson

Bob Garry - I have not been able to contact Bob. Please forward if you can.

Christian Drosten

Tony Fauci

Mike Ferguson

Ron Fouchier

Eddie Holmes

Marion Koopmans

Stefan Pohlmann

Andrew Rambaut

Paul Schreier

Patrick Vallance

Sent: Sat, 1 Feb 2020 18:12:57 +0000

To: Fauci, Anthony (NIH/NIAID) [E];Patrick Vallance

Cc: Drosten, Christian; Marion Koopmans; R.A.M. Fouchier; Edward

Holmes; (b) (6);Andrew Rambaut;Kristian G. Andersen;Paul Schreier (b) (6);Ferguson, Mike;Collins, Francis (NIH/OD) [E]

Subject: Re: Teleconference

Attachments: Coronavirus sequence comparison[1].pdf

Kristen and Eddie have shared this and will talk through it on the call. Thank you.

Hope it will help frame the discussions.

From: Jeremy Farrar (b) (6)

Date: Saturday, 1 February 2020 at 15:34

1st February (2nd Feb for Eddie)

Information and discussion is shared in total confidence and not to be shared until agreement on next steps.

Dial in details attached.

Please mute phones.

I will be on email throughout - email Paul or I Paul if any problems

If you cannot make it, I will phone you afterwards to update.

One Hour

6am Sydney

8pm CET

7pm GMT

2pm EST

11am PST

(Hope I have the times right!)

Thank you for the series of calls and for agreeing to join this call.

Agenda

· Introduction, focus and desired outcomes - JF

- Summary KA
- Comments EH
- Q&A All

Paul Schreier Patrick Vallance

• Summary and next steps - JF

Kristian Anderson
Bob Garry - I have not been able to contact Bob. Please forward if you can.
Christian Drosten
Tony Fauci
Mike Ferguson
Ron Fouchier
Eddie Holmes
Marion Koopmans
Stefan Pohlmann
Andrew Rambaut

From: Jeremy Farrar

Sent: Sat, 1 Feb 2020 16:12:51 +0000

To: Fauci, Anthony (NIH/NIAID) [E]; Patrick Vallance

Cc: Drosten, Christian; Marion Koopmans; R.A.M. Fouchier; Edward

Holmes; (b) (6);Andrew Rambaut;Kristian G. Andersen;Paul Schreier (b) (6);Ferguson, Mike;Collins, Francis (NIH/OD) [E]

Subject: Re: Teleconference

Dial in details

(b) (6)

Participant Code - (b) (6)

(b) (6) From: Jeremy Farrar Date: Saturday, 1 February 2020 at 15:34 To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6), Patrick Vallance (b) (6) (b) (6), Marion Koopmans Cc: "Drosten, Christian" (b) (6) (b) (6) (b) (6) **Edward Holmes** (b) (6) (b) (6)11 (b) (6) (b) (6) " (b) (6), "Kristian G. Andersen" (b) (6) (b) (6), Paul Schreier

Subject: Teleconference

1st February (2nd Feb for Eddie)

Information and discussion is shared in total confidence and not to be shared until agreement on next steps.

(b) (6)

Dial in details attached.

Please mute phones.

I will be on email throughout - email Paul or I Paul if any problems

If you cannot make it, I will phone you afterwards to update.

(b) (6), Michael FMedSci

One Hour

6am Sydney

8pm CET

7pm GMT

2pm EST

11am PST

(Hope I have the times right!)

Thank you for the series of calls and for agreeing to join this call.

Agenda

- Introduction, focus and desired outcomes JF
- Summary KA
- Comments EH
- Q&A All
- Summary and next steps JF

Kristian Anderson

Bob Garry - I have not been able to contact Bob. Please forward if you can.

Christian Drosten

Tony Fauci

Mike Ferguson

Ron Fouchier

Eddie Holmes

Marion Koopmans

Stefan Pohlmann

Andrew Rambaut

Paul Schreier

Patrick Vallance

From: Jeremy Farrar

Sent: Sat, 1 Feb 2020 15:51:54 +0000

To: Fauci, Anthony (NIH/NIAID) [E]; Garry, Robert F

Cc: Patrick Vallance; Drosten, Christian; Marion Koopmans; R.A.M. Fouchier; Edward

Holmes; (b) (6) Andrew Rambaut; Kristian G. Andersen; Paul Schreier; Ferguson,

Mike; Collins, Francis (NIH/OD) [E]; Tabak, Lawrence (NIH/OD) [E]

Subject: Re: Teleconference

Francis Call me on

(b) (6)

From: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)

Date: Saturday, 1 February 2020 at 15:50

To: "Garry, Robert F" (b) (6), Jeremy Farrar

Cc: Patrick Vallance (b) (6), "Drosten, Christian"

(b) (6)

(b) (6)

Francis Collins (b) (6) "Tabak, Lawrence (NIH/OD) [E]"

Subject: RE: Teleconference

Please include Francis Collins (copied here) on all subsequent correspondence regarding this call. Thanks.

From: Garry, Robert F (b) (6)

Sent: Saturday, February 1, 2020 10:49 AM

To: Jeremy Farrar (b) (6)

Cc: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Patrick Vallance (b) (6); Drosten, Christian (b) (6); Marion Koopmans (b) (6); R.A.M. Fouchier (b) (6); Edward Holmes (b) (6); Andrew Rambaut

Kristian G. Andersen (b) (6); Paul Schreier (b) (6); Ferguson,

Mike (b) (6)

Subject: Re: Teleconference

Thanks Jeremy

I will be on the call

Bob Garry

Sent from my iPhone

On Feb 1, 2020, at 9:34 AM, Jeremy Farrar

(b) (6) > wrote:

External Sender. Be aware of links, attachments and requests.

1st February (2nd Feb for Eddie)

Information and discussion is shared in total confidence and not to be shared until agreement on next steps.

Dial in details attached.

Please mute phones.

I will be on email throughout – email Paul or I Paul if any problems If you cannot make it, I will phone you afterwards to update.

One Hour

6am Sydney 8pm CET 7pm GMT 2pm EST 11am PST (Hope I have the times right!)

Thank you for the series of calls and for agreeing to join this call.

Agenda

- · Introduction, focus and desired outcomes JF
- Summary KA
- Comments EH
- Q&A All
- Summary and next steps JF

Kristian Anderson
Bob Garry - I have not been able to contact Bob. Please forward if you can.
Christian Drosten
Tony Fauci
Mike Ferguson
Ron Fouchier

Eddie Holmes Marion Koopmans Stefan Pohlmann Andrew Rambaut Paul Schreier Patrick Vallance

Wellcome exists to improve health by helping great ideas to thrive. We support researchers, we take on big health challenges, we campaign for better science, and we help everyone get involved with science and health research. We are a politically and financially independent foundation.

The Wellcome Trust is a charity registered in England and Wales, no. 210183. Its sole trustee is The Wellcome Trust Limited, a company registered in England and Wales, no. 2711000 (whose registered office is at 215 Euston Road, London NW1 2BE, UK)

<Teleconference Dial In.jpg>

From: Jeremy Farrar

Sent: Sat, 1 Feb 2020 15:50:28 +0000 To: Fauci, Anthony (NIH/NIAID) [E] Cc: Collins, Francis (NIH/OD) [E]

Subject: Re: Teleconference

excellent

From: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6);>

Date: Saturday, 1 February 2020 at 15:48 (b) (6) To: Jeremy Farrar (b) (6)

Cc: Francis Collins

Subject: RE: Teleconference

Jeremy:

Francis will be on the call. He is trying to phone you.

Tony

(b)(6)From: Jeremy Farrar Sent: Saturday, February 1, 2020 10:34 AM To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) Patrick Vallance (b) (6) (b) (6); Marion Koopmans Cc: Drosten, Christian (b) (6); R.A.M. Fouchier (b) (6) Edward Holmes (b) (6); (b) (6) (b) (6) Andrew Rambaut Kristian G. Andersen (b) (6) Paul Schreier (b) (6); (b) (6) Ferguson, Mike (b) (6)

Subject: Teleconference

1st February (2nd Feb for Eddie)

Information and discussion is shared in total confidence and not to be shared until agreement on next steps.

Dial in details attached.

Please mute phones.

I will be on email throughout - email Paul or I Paul if any problems

If you cannot make it, I will phone you afterwards to update.

One Hour

6am Sydney 8pm CET

7pm GMT

2pm EST

11am PST (Hope I have the times right!)

Thank you for the series of calls and for agreeing to join this call.

Agenda

- · Introduction, focus and desired outcomes JF
- Summary KA
- Comments EH
- Q&A All
- Summary and next steps JF

Kristian Anderson
Bob Garry - I have not been able to contact Bob. Please forward if you can.
Christian Drosten
Tony Fauci
Mike Ferguson
Ron Fouchier
Eddie Holmes
Marion Koopmans
Stefan Pohlmann
Andrew Rambaut
Paul Schreier
Patrick Vallance

Wellcome exists to improve health by helping great ideas to thrive. We support researchers, we take on big health challenges, we campaign for better science, and we help everyone get involved with science and health research. We are a politically and financially independent foundation.

The Wellcome Trust is a charity registered in England and Wales, no. 210183. Its sole trustee is The Wellcome Trust Limited, a company registered in England and Wales, no. 2711000 (whose registered office is at 215 Euston Road, London NW1 2BE, UK)

From: Jeremy Farrar

Sent: Sat, 1 Feb 2020 13:27:42 +0000 **To:** Fauci, Anthony (NIH/NIAID) [E]

Subject: Re: Conf details

Thanks Tony!

I will make sure we have the correct times.

On 01/02/2020, 13:26, "Fauci, Anthony (NIH/NIAID) [E]" (b) (6) > wrote:

Jeremy

I can be on the 2:00 PM EST call (8:00 PM CET). Note for West Coast callers, that 2:00 PM EST equal 11:00 AM West Coast and not 9:00 AM West Coast

Thanks, Tony

----Original Message----

From: Jeremy Farrar (b) (c) Sent: Saturday, February 1, 2020 5:55 AM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>

Subject: Re: Conf details

Could you join?

Trying to set up an initial call with

Kristian Anderson

Bob Garry

Christian Drosten

Tony Fauci

Ron Fouchier

Eddie Holmes

Marion Koopmans

Patrick Vallance - Chief Scientist UK

Time zones a challenge

Suggestion - Today 1st February (2nd Feb for Eddie) - I Will confirm later today. If you cannot make it, we will phone you afterwards to update.

6am Sydney

8pm CET

7pm GMT

2pm EST

9am West Coast

My preference is to keep this really tight group.

To listen to the work Eddie, Bob and Kristian have done.

Question it

And think through next steps.

Obviously ask everyone to treat in total confidence.

From: Jeremy Farrar

Sent: Sat, 1 Feb 2020 10:55:15 +0000 **To:** Fauci, Anthony (NIH/NIAID) [E]

Subject: Re: Conf details
Attachments: IMG_1781[2].JPG

Could you join?

Trying to set up an initial call with

Kristian Anderson
Bob Garry
Christian Drosten
Tony Fauci
Ron Fouchier
Eddie Holmes
Marion Koopmans

Patrick Vallance - Chief Scientist UK

Time zones a challenge

Suggestion - Today 1st February (2nd Feb for Eddie) - I Will confirm later today. If you cannot make it, we will phone you afterwards to update.

6am Sydney 8pm CET 7pm GMT 2pm EST 9am West Coast

My preference is to keep this really tight group.

To listen to the work Eddie, Bob and Kristian have done.

Question it

And think through next steps.

Obviously ask everyone to treat in total confidence.



wellcometrust

Chairman's Office

MeetingSpace No:

International No:

Participant Access Code:

Host Access Code:

From: Fauci, Anthony (NIH/NIAID) [E]

Sent: Sat, 1 Feb 2020 02:47:39 +0000

To: Jeremy Farrar; Kristian G. Andersen

Subject: FW: Science: Mining coronavirus genomes for clues to the outbreak's origins

Jeremy/Kristian:

This just came out today. You may have seen it. If not, it is of interest to the current discussion.

Best, Tony

From: Folkers, Greg (NIH/NIAID) [E] (b) (6)

Sent: Friday, January 31, 2020 8:43 PM

Subject: Science: Mining coronavirus genomes for clues to the outbreak's origins



As part of a long-running effort to see what viruses bats harbor, researchers in China collect one from a cave in Guandong.

EcoHealth Alliance

Mining coronavirus genomes for clues to the outbreak's origins

By Jon Cohen Jan. 31, 2020, 6:20 PM

attaaaggtt tataccttcc caggtaacaa accaaccaac tttcgatctc ttgtagatct ...


That string of apparent gibberish is anything but: It's a snippet of a DNA sequence from the viral pathogen, dubbed 2019 novel coronavirus (2019-nCoV), that is overwhelming China and frightening the entire world. Scientists are publicly sharing an ever-growing number of full sequences of the virus from patients—53 at last count in the Global Initiative on Sharing All Influenza Data database. These viral genomes are being intensely studied to try to understand the origin of 2019-nCoV and how it fits on the family tree of related viruses found in bats and other species. They have also given glimpses into what this newly discovered virus physically looks like, how it's changing, and how it might be stopped.

"One of the biggest takeaway messages [from the viral sequences] is that there was a single introduction into humans and then human-to-human spread," says Trevor Bedford, a bioinformatics specialist at the University of Washington, Seattle. The role of Huanan Seafood Wholesale Market in Wuhan, China, in spreading 2019-nCoV remains murky, though such sequencing, combined with sampling the market's environment for the presence of the virus, is clarifying that it indeed had an important early role in amplifying the outbreak. The viral sequences, most researchers say, also knock down the idea the pathogen came from a virology institute in Wuhan.

In all, 2019-nCoV has nearly 29,000 nucleotides bases that hold the genetic instruction book to produce the virus. Although it's one of the many viruses whose genes are in the form of RNA, scientists convert the viral genome into DNA, with bases known in shorthand as A, T, C, and G, to make it easier to study. Many analyses of 2019-nCoV's sequences have already appeared on virological.org, nextstrain.org, preprint servers like bioRxiv, and even in peer-reviewed journals. The sharing of the sequences by Chinese researchers allowed public health labs around the world to develop their own diagnostics for the virus, which now has been found in 18 other countries. (*Science*'s news stories on the outbreak can be found here.)


When the first 2019-nCoV sequence became available, researchers placed it on a family tree of known coronaviruses—which are abundant and infect many species—and found that it was most closely related to relatives found in bats. A team led by Shi Zheng-Li, a coronavirus specialist at the Wuhan Institute of Virology, reported on 23 January on bioRxiv that 2019-nCoV's sequence was 96.2% similar to a bat virus and had 79.5% similarity to the coronavirus that causes severe acute respiratory syndrome (SARS), a disease whose initial outbreak was also in China more than 15 years ago. But the SARS coronavirus has a similarly close relationship to bat viruses, and sequence data make a powerful case that it jumped into people from a coronavirus in civets that differed from human SARS viruses by as few as 10 nucleotides. That's one reason why many scientists suspect there's an "intermediary" host species—or several—between bats and 2019-nCoV.

According to Bedford's analysis, the bat coronavirus sequence that Shi Zheng-Li's team highlighted, dubbed RaTG13, differs from 2019-nCoV by nearly 1100 nucleotides. On nextstrain.org, a site he cofounded, Bedford has created coronavirus family trees (example below) that include bat, civet, SARS, and 2019-nCoV sequences. (The trees are interactive—by dragging a computer mouse over them, it's easy to see the differences and similarities between the sequences.)



Bedford's analyses of RaTG13 and 2019-nCoV suggest that the two viruses shared a common ancestor 25 to 65 years ago, an estimate he arrived at by combining the difference in nucleotides between the viruses with the presumed rates of mutation in other coronaviruses. So it likely took decades for RaTG13-like viruses to mutate into 2019-nCoV.

Middle East respiratory syndrome (MERS), another human disease caused by a coronavirus, similarly has a link to bat viruses. But studies have built a compelling case it jumped to humans from camels. And the phylogenetic tree from Shi's bioRxiv paper (below) makes the camel-MERS link easy to see.



The longer a virus circulates in a human populations, the more time it has to develop mutations that differentiate strains in infected people, and given that the 2019-nCoV sequences analyzed to date differ from each other by seven nucleotides at most, this suggests it jumped into humans very recently. But it remains a mystery which animal spread the virus to humans. "There's a very large gray area between viruses detected in bats and the virus now isolated in humans," says Vincent Munster, a virologist at the U.S. National Institute of Allergy and Infectious Diseases who studies coronaviruses in bats, camels, and others species.

Strong evidence suggests the marketplace played an early role in spreading 2019-nCoV, but whether it was the origin of the outbreak remains uncertain. Many of the initially confirmed 2019-nCoV cases—27 of the first 41 in one report, 26 of 47 in another—were connected to the Wuhan market, but up to 45%, including the earliest handful, were not. This raises the possibility that the initial jump into people happened elsewhere.

According to Xinhua, the state-run news agency, "environmental sampling" of the Wuhan seafood market has found evidence of 2019-nCoV. Of the 585 samples tested, 33 were positive for 2019-nCoV and all were in the huge market's western portion, which is where wildlife were sold. "The positive tests from the wet market are hugely important," says Edward Holmes, an evolutionary biologist at the University of Sydney who collaborated with the <u>first group</u> to publicly release a 2019-nCoV sequence. "Such a high rate of positive tests would strongly imply that animals in the market played a key role in the emergence of the virus."

Yet there have been no preprints or official scientific reports on the sampling, so it's not clear which, if any, animals tested positive. "Until you consistently isolate the virus out of a single species, it's really, really difficult to try and determine what the natural host is," says Kristian Andersen, an evolutionary biologist at Scripps Research.

One possible explanation for the confusion about where the virus first entered humans is if there was a batch of recently infected animals sold at different marketplaces. Or an infected animal trader could have transmitted the virus to different people at different markets. Or, Bedford suggests, those early cases could have been infected by viruses that didn't easily transmit and sputtered out. "It would be hugely helpful to have just a sequence or two from the marketplace [environmental sampling] that could illuminate how many zoonoses occurred and when they occurred," Bedford says.



A research group sent fecal and other bodily samples from bats they trapped in caves to the Wuhan Institute of Virology to search for coronaviruses.

EcoHealth Alliance

In the absence of clear conclusions about the outbreak's origin, theories thrive, and some have been scientifically shaky. A sequence analysis led by Wei Ji of Peking University and published online by the *Journal of Medical Virology* received substantial press coverage when it suggested that "snake is the most probable wildlife animal reservoir for the 2019-nCoV." Sequence specialists, however, <u>pilloried it</u>. Conspiracy theories also abound. A CBC News report about the Canadian government deporting Chinese scientists who worked in a Winnipeg lab that studies dangerous pathogens <u>was distorted on social media</u> to suggest that they were spies who had smuggled out coronaviruses. The Wuhan Institute of Virology, which is the premier lab in China that studies bat and human coronaviruses, has also come under fire. "Experts debunk fringe theory linking China's coronavirus to weapons research," read a headline on a story in *The Washington Post* that focused on the facility.

Concerns about the institute predate this outbreak. *Nature* ran a story in 2017 about it building a new biosafety level 4 lab and included molecular biologist Richard Ebright of Rutgers University, Piscataway, expressing concerns about accidental infections, which he noted repeatedly happened with lab workers handling <u>SARS</u> in <u>Beijing</u>. Ebright, who has a long history of raising red flags about studies with

dangerous pathogens, also in 2015 <u>criticized an experiment</u> in which modifications were made to a SARS-like virus circulating in Chinese bats to see whether it had the potential to cause disease in humans. Earlier this week, Ebright <u>questioned the accuracy</u> of Bedford's calculation that there are at least 25 years of evolutionary distance between RaTG13—the virus held in the Wuhan virology institute—and 2019-nCoV, arguing that the mutation rate may have been different as it passed through different hosts before humans. Ebright tells *Science*Insider that the 2019-nCoV data are "consistent with entry into the human population as a natural accident."

Shi did not reply to emails from *Science*, but her longtime collaborator, disease ecologist Peter Daszak of the EcoHealth Alliance, dismissed Ebright's conjecture. "Every time there's an emerging disease, a new virus, the same story comes out: This is a spillover or the release of an agent or a bioengineered virus," Daszak says. "It's just a shame. It seems humans can't resist controversy and these myths, yet it's staring us right in the face. There's this incredible diversity of viruses in wildlife and we've just scratched the surface. Within that diversity, there will be some that can infect people and within that group will be some that cause illness."



A team of researchers from the Wuhan Institute of Virology and the EcoHealth Alliance have trapped bats in caves all over China, like this one in Guangdong, to sample them for coronaviruses. EcoHealth Alliance


Daszak and Shi's group have for 8 years been trapping bats in caves around China to sample their feces and blood for viruses. He says they have sampled more than 10,000 bats and 2000 other species. They have found some 500 novel coronaviruses, about 50 of which fall relatively close to the SARS virus on the family tree, including RaTG13—it was fished out of a bat fecal sample they collected in 2013 from a cave in Moglang in Yunnan province. "We cannot assume that just because this virus from Yunnan has high sequence identity with the new one that that's the origin," Daszak says, noting that only a tiny fraction of coronaviruses that infect bats have been discovered. "I expect that once we've sampled and sampled and sampled across southern China and central China that we're going to find many other viruses and some of them will be closer [to 2019-nCoV]."

It's not just a "curious interest" to figure out what sparked the current outbreak, Daszak says. "If we don't find the origin, it could still be a raging infection at a farm somewhere, and once this outbreak dies, there could be a continued spillover that's really hard to stop. But the jury is still out on what the real origins of this are."

Posted in:

- Asia/Pacific
- Health

• Coronavirus doi:10.1126/science.abb1256



Jon Cohen
Jon is a staff writer for *Science*.

- Email Jon
- Twitter

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 1 Feb 2020 00:38:35 +0000

To: Jeremy Farrar
Cc: Kristian G. Andersen

Bcc: Conrad, Patricia (NIH/NIAID) [E];Mascola, John (NIH/VRC) [E];Conrad, Patricia

(NIH/NIAID) [E]

Subject: RE: Phone call

Jeremy:

(b) (5)

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone:
(b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jeremy Farrar (b) (6)

Sent: Friday, January 31, 2020 5:57 PM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)

Subject: Re: Phone call

Thanks Tony

Can you phone Kristian Anderson

(b) (6)

He is expecting your call now.

The people involved are:

Kristian Anderson

https://www.scripps.edu/faculty/andersen/

Bob Garry

https://medicine.tulane.edu/departments/microbiology-immunology-tulane-cancer-center/faculty/robert-f-garry-jr-phd

Eddie Holmes

https://sydney.edu.au/science/about/our-people/academic-staff/edward-holmes.html

From: "Conrad, Patricia (NIH/NIAID) [E]" (b) (6) > on behalf of "Fauci,

Anthony (NIH/NIAID) [E]" (6) (6)

Date: Friday, 31 January 2020 at 22:34

To: Jeremy Farrar (b) (6)

Subject: RE: Phone call

Will call shortly...

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892

(b) (6)

(b) (6)

301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept

liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jeremy Farrar	(b) (6)	
Sent: Friday, January 31, 2020 5:23	PM	
To: Fauci, Anthony (NIH/NIAID) [E]		(b) (6)
Subject: Phone call		
Tony		
Really would like to speak with you	this evening	
It is 10pm now UK		
Can you phone me on ((b) (6)	
Jeremy		

Wellcome exists to improve health by helping great ideas to thrive. We support researchers, we take on big health challenges, we campaign for better science, and we help everyone get involved with science and health research. We are a politically and financially independent foundation.

The Wellcome Trust is a charity registered in England and Wales, no. 210183. Its sole trustee is The Wellcome Trust Limited, a company registered in England and Wales, no. 2711000 (whose registered office is at 215 Euston Road, London NW1 2BE, UK)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Jan 2020 14:26:15 +0000

To: Jeremy Farrar
Cc: Patrick Vallance
Subject: Re: Contacts

Thanks, Jeremy. Great chatting with you and Patrick. Will stay in close touch. Best,

Tony

> Wellcome exists to improve health by helping great ideas to thrive. We support researchers, we take on big health challenges, we campaign for better science, and we help everyone get involved with science and health research. We are a politically and financially independent foundation.

> The Wellcome Trust is a charity registered in England and Wales, no. 210183. Its sole trustee is The Wellcome Trust Limited, a company registered in England and Wales, no. 2711000 (whose registered office is at 215 Euston Road, London NW1 2BE, UK)

From: Jeremy Farrar

Sent: Wed, 29 Jan 2020 20:43:32 +0000 **To:** Fauci, Anthony (NIH/NIAID) [E]

Subject: Re: Informal coronavirus teleconference, 29 January, 19.00 CET

So kind!!

From: "Conrad, Patricia (NIH/NIAID) [E]" (b) (6) > on behalf of "Fauci,

Anthony (NIH/NIAID) [E]" (b) (6)

Date: Wednesday, 29 January 2020 at 20:42
To: Jeremy Farrar (b) (6)

Subject: RE: Informal coronavirus teleconference, 29 January, 19.00 CET

Ok – we will try to call you early morning our time tomorrow. Thanks.

Patricia L. Conrad
Public Health Analyst and

Special Assistant to the Director

special Assistant to the Director

National Institute of Allergy and Infectious Diseases

The National Institutes of Health

31 Center Drive, MSC 2520 - Room 7A03

Bethesda, Maryland 20892

(b) (6)

301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jeremy Farrar (b) (6)
Sent: Wednesday, January 29, 2020 3:40 PM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)

Subject: Re: Informal coronavirus teleconference, 29 January, 19.00 CET

Will probably run over at the WH. Thank you and him so much!

Tomorrow is fine.

On 29 Jan 2020, at 20:38, Fauci, Anthony (NIH/NIAID) [E] (b) (6) wrote:

Dr Fauci is in meeting at the WH until about 5 pm ET so he would likely call you between 5 pm - 7 pm ET – is that too late today?

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892

(b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jeremy Farrar Sent: Wednesday, January 29, 2020 2:35 PM To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) > Subject: Re: Informal coronavirus teleconference, 29 January, 19.00 CET Sure Anytime -(b) (6) Tonight from 5pm would be fine, but tomorrow also possible.... From: "Conrad, Patricia (NIH/NIAID) [E]" (b) (6) on behalf of "Fauci, Anthony (NIH/NIAID) [E]" (b) (6) Date: Wednesday, 29 January 2020 at 19:29 To: Jeremy Farrar (b) (6), "Fauci, Anthony (NIH/NIAID) [E]" (b) (6) Subject: RE: Informal coronavirus teleconference, 29 January, 19.00 CET

Is there a cell number to reach you? or best number?

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases

The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)

301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jeremy Farrar (b) (6) (6) Sent: Wednesday, January 29, 2020 2:21 PM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)

Subject: Re: Informal coronavirus teleconference, 29 January, 19.00 CET

I could not make it until 5pm CET today. But next few days also OK.

From: "Conrad, Patricia (NIH/NIAID) [E]" (b) (6) on behalf of "Fauci,

Anthony (NIH/NIAID) [E]" (b) (6)

Date: Wednesday, 29 January 2020 at 18:54

To: Jeremy Farrar (b) (6)

Subject: RE: Informal coronavirus teleconference, 29 January, 19.00 CET

Dr Fauci is in back to back meetings but hopes to be able to step out and call you between 3:00 pm ET - 4:00 pm ET. Is that time ok and what is the best number to reach you at that time?

Best,

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892

(b) (6)

Disclaimer:

301-496-4409 fax

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it


from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jeremy Farrar (b) (6)
Sent: Wednesday, January 29, 2020 1:32 PM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)

Subject: Re: Informal coronavirus teleconference, 29 January, 19.00 CET

Tony - Would be very keen to hear your personal views on n-CoV. If you have 5 mins for a phone call. Best wishes Jeremy



Mike:

I am sorry but I have an important meeting with Secretary Azar that is a prep meeting for another important meeting at the White House. These overlap with the 19:00 CET time frame of your call. Unless something changes I cannot be on the call. If that is the case, I will ask Hilary Marston from my staff to fill in for me and report back to me. Please send the call in information to my Special Assistant, Patty Conrad, and me just in case something changes. Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone:
(b) (6)
FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: RYAN, Michael .	J. (b) (6)			
Sent: Wednesday, Jan	uary 29, 2020 10:45 A	M		
To: Redfield, Robert R	. (CDC/OD)	(b) (6) >		(b) (6)
			David Heymann	(b) (6);
(b) (6); Chris.Elias			David Heymann	(b) (6)
				; Fauci, Anthony
(NIH/NIAID) [E]	(b) (6);			(b) (6)
	; COX, Paul Michael		(b) (6); SHOC	(b) (6); GREIN, Thomas
(b) (6)				
Cc: GHEBREYESUS, Tedros Adhanom			(b) (6); SCHWARTLAND	DER, Bernhard F.
	(b) (6); MINHAS, Rama	an	(b) (6)	
Subject: Informal coro	navirus teleconferenc	e, 29 .	January, 19.00 CET	

Dear colleagues,

Dr Tedros would like to take the opportunity to informally discuss with you the ongoing 2019 novel coronavirus.

We are planning to host a teleconference today at 19.00 CET and will provide a dial-in number with a passcode.

If you face any difficulties with the dial-in number, please provide us with a contact number and we will attempt to dial you in.

Best,

Mike

From: Fauci, Anthony (NIH/NIAID) [E] Sent: Wed, 29 Jan 2020 11:36:40 +0000

To: Dzau, Victor J.; GPMB Secretariat'; As Sy Elhadi; Brundtland Gro Harlem; Chris. Elias; Farrar Jeremy; Fore Henrietta; Gao Fu; Gashumba Diane; Kaag Sigrid; Ilona Kickbusch; Suzuki Yasuhiro; Vega Morales Jeanette; Vega Morales Jeanette; Vijay Raghavan Krishnaswamy; 'Skvortsova Veronika'

Cc: MAHJOUR, Jaouad; MINHAS, Raman; Toomas Palu; Pate Muhamed; RYAN, Michael J.; SCHWARTLANDER, Bernhard F.; Alex Harris; Alveberg, Benedikte Louise; Chiaki NOGUCHI; Esveld Marja; Esveld Marja; Gonggrijp Mette; Julie. HALL; Kanarek, Morgan; Marston, Hilary (NIH/NIAID) [E]; Omar Abdi; Amelie RIOUX; Tore Godal; GABEDAVA, Tsira; ROSS, Alex; Banks Lynn; Block, Bruce; Conrad Jane; Conrad, Patricia (NIH/NIAID) [E]; Del Sol Dinia; Diao Fay;Gahungu Zacharie;Harikumar M K;Harikumar M K;Kabagire Christine;KITA Yosuke Miller de Vega Teresa; MURIUKI, Hilda Wairimu; Muzenda Sindiso; Sarah Belmir; YU Bai; Kirsi; (b) (6); 'Oleg Sonin'; Marston, Hilary (NIH/NIAID) [E] Madi

RE: TIME SENSITIVE Message from GPMB Co-Chairs: review of draft GPMB Subject:

Statement on 2019-novel coronavirus

Attachments: Draft GPMB Statement nCOV 28Jan for Bd member review NIAID.docx

Looks fine. Please see my comments in attached document. Thanks, Tony

From: Dzau, Victor J. <VDzau@nas.edu> Sent: Tuesday, January 28, 2020 11:46 PM To: 'GPMB Secretariat' (b) (6); As Sy Elhadi (b) (6); Brundtland Gro Harlem (b) (6); Chris. Elias (b) (6) >; Farrar Jeremy (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6); Fore Henrietta (b) (6) Gao Fu (b) (6) >; Gashumba Diane (b) (6); Kaag (b) (6) >; Suzuki Yasuhiro < (b) (6) Sigric (b) (6) Ilona Kickbusch Vega Morales Jeanette < (b) (6); Vega Morales Jeanette (b) (6); VijayRaghavan Krishnaswamy (b) (6); 'Skvortsova Veronika' (b)(6) >Cc: MAHJOUR, Jaouad (b) (6); MINHAS, Raman (b) (6); Toomas Palu (b) (6); Pate Muhamed (b) (6); RYAN, Michael J. (b) (6); SCHWARTLANDER, Bernhard F. (b) (6) Alex Harris (b) (6); Alveberg, Benedikte Louise (b) (6) Chiaki (b) (6); Esveld Marja (b) (6); Esveld Marja NOGUCHI (b) (6); Esveld Marja (b) (6); Gonggrijp Mette (b) (6) (b) (6) Marston, Hilary (NIH/NIAID) (b) (6) Kanarek, Morgan Julie.HALL (b) (6); Amelie RIOUX (b) (6); Omar Abdi [E] (b) (6); Tore Godal (b) (6); GABEDAVA, Tsira (b) (6); (b) (6); Banks Lynn ROSS, Alex (b) (6); Block, Bruce <BBlock@nas.edu>; Conrad Jane (b) (6) Conrad, Patricia (NIH/NIAID) [E] (b) (6) Del Sol Dinia (b) (6); Diao Fay (b) (6) >; Gahungu Zacharie (b) (6); Harikumar M K (b) (6) Harikumar M K <office-psa@nic.in>; Kabagire Christine (b) (6) >; KITA Yosuke

```
(b) (6); (b) (6) Miller de Vega Teresa
(b) (6); MURIUKI, Hilda Wairimu (b) (6); Muzenda Sindiso
(b) (6); Sarah Belmir (b) (6); YU Bai (b) (6); Kirsi Madi
(b) (6) 'Oleg Sonin' (b) (6)
```

Subject: RE: TIME SENSITIVE Message from GPMB Co-Chairs: review of draft GPMB Statement on 2019-novel coronavirus

The message is clear and appropriate. I support it.

From: GPMB	Secretariat		(b) (6)			
Sent: Tuesda	y, January 28, 202	0 7:09 AM				
To: As Sy Elh	adj	(b) (6); Brundtland	Gro Harlem		(b) (б) >; Dzau,	Victor J.
<vdzau@nas< td=""><td>s.edu>; Chris.Elias</td><td></td><td></td><td>(6)>; Farrar Jer</td><td></td><td></td></vdzau@nas<>	s.edu>; Chris.Elias			(6)>; Farrar Jer		
	(b) (6); Fa	auci Anthony	(b) (6)>; Fore Hei	nrietta	(b) (6);
Gao Fu	(b) (6);	Gashumba Diane		(b) (б); Kaa	g Sigrid	(b) (6);
Ilona Kickbus	sch	(b) (б)>; Suzuki	Yasuhiro		(b) (6) >; V	
Morales Jear	nette	(b) (6); Vega Mora	les Jeanette		(b) (6);
VijayRaghava	an Krishnaswamy		(b) (6) 'Skvor	tsova Veronika	ı	(b) (6)
Cc: MAHJOU	R, Jaouad	(b) (6); MIN	IHAS, Raman		(b) (6); Toomas	Palu
	(b) (6) >; Pate	Muhamed		(b) (6) RYAN, N	1ichael J.	
	(b) (6) >; SCHWARTI	ANDER, Bernhard		(b) (6)>; Alex Harris	
	(b) (6); A	veberg, Benedikte	Louise		(b) (6)	>; Chiaki
NOGUCHI		(b) (б); Esv	eld Marja		(b) (6) >; Esv	eld Marja
	(b) (б) Esveld Ma	arja (b) (6) >; Gonggr	rijp Mette		(b) (6);
Julie.HALL	(b) (6	>; Kanarek, Morga	an	(b) (6); N	Narston Hilary	
	(b) (6)>; On	nar Abdi	(b) (6)>;	Amelie RIOUX		(b) (6);
Tore Godal	(b) (d)>; GABEDAVA, Ts	ira	(b) (6)	ROSS, Alex	
	(6) (6); Banks Lynn			ம்) (6); Block, Bri	uce	(b) (6) >;
Conrad Jane		(b) (6); Conrad Patri	cia	(b) (б	5>; Del Sol Dinia	ľ
	(b) (6); Diao Fa	У	(b) (6) ; Gahu	ngu Zacharie		
	(b)	何>; Harikumar M	K	(b)	(6); Harikumar N	VIK < (b) (6)
	Kabagire Christin	e		(b) (6); KITA Yos		
	>;		(b) (6)	Miller de Vega	Teresa (6)	
		6) (6); MURIUKI, Hi	lda Wairimu		(b) (6); Muzend	a Sindiso
	(b) (6); S	arah Belmir	Œ	6) (6) YU Bai	(b) (6) >;	Kirsi Madi
		(b) (б); 'Ole	g Sonin '		(b) (6) >	
Subject: TIM	F SENSITIVE MASS	age from GPMR Co	-Chairs revie	w of draft GPN	AR Statement or	2019-

Dear Board members,

novel coronavirus Importance: High

Thank you to all who participated in yesterday's teleconference call regarding the novel 2019-Coronavirus outbreak.

We received excellent updates from WHO and from Professor Gao.

There was consensus for the GPMB to issue a statement supportive of countries' (especially China) and WHO response efforts, and to call for urgent actions to further strengthen global preparedness and response to this outbreak.

Please find attached a draft GPMB Statement.

We ask that you please send us any feedback (preferably in track change mode) no later than <u>1700</u> Wednesday 29 January, Geneva time

Thank you very much.	
Kinds regards,	
Gro and As	

From: Jeremy Farrar

Sent: Tue, 28 Jan 2020 21:13:22 +0000

To: Jeanette Vega Morales;GPMB Secretariat;As Sy Elhadj;Brundtland Gro Harlem;Dzau Victor;Chris.Elias;Fauci, Anthony (NIH/NIAID) [E];Fore Henrietta;Gao Fu;Gashumba Diane;Kaag Sigrid;Ilona Kickbusch;Suzuki Yasuhiro;Vega Morales Jeanette;Vega Morales Jeanette;VijayRaghavan Krishnaswamy;'Skvortsova Veronika'

Cc: MAHJOUR, Jaouad; MINHAS, Raman; Toomas Palu; Pate Muhamed; RYAN, Michael J.; SCHWARTLANDER, Bernhard F.; Alex Harris; Alveberg, Benedikte Louise; Chiaki NOGUCHI; Esveld Marja; Esveld Marja; Esveld Marja; Gonggrijp Mette; Julie. HALL; Kanarek Morgan; Marston, Hilary (NIH/NIAID) [E]; Omar Abdi; Amelie RIOUX; Tore Godal; William Hall; GABEDAVA, Tsira; ROSS, Alex; Banks Lynn; Block Bruce; Conrad Jane; Conrad, Patricia (NIH/NIAID) [E]; Del Sol Dinia; Diao Fay; Gahungu Zacharie; Harikumar M K; Harikumar M K; Kabagire Christine; KITA Yosuke; (b) (6) ; Teresa Miller de Vega; MURIUKI, Hilda Wairimu; Muzenda Sindiso; Sarah Belmir; YU Bai; Kirsi Madi (b) (6); Oleg Sonin '; Alice Jamieson; Alex Harris

Subject: Re: TIME SENSITIVE Message from GPMB Co-Chairs: review of draft GPMB

Statement on 2019-novel coronavirus

Attachments: Draft GPMB Statement_nCOV_28Jan_for Bd member review_JF.docx

Suggestions - thank you

From: Jeanette Veg	ga Morales	(b) (6)			
Date: Tuesday, 28.	January 2020 at 14:38				
To: GPMB Secretar	iat	(b) (6)·, As	Sy Elhadj		(b) (6)
Brundtland Gro Ha	rlem	(b) (6), Victor	Dzau <vdza< td=""><td>au@nas.edu>,</td><td>"Chris.Elias"</td></vdza<>	au@nas.edu>,	"Chris.Elias"
	(b) (6), Jerer	my Farrar		(b) (6), F	auci Anthony
	(b) (6) Fore Henrietta		(b) (6), Gao I	Fu	(b) (6)
Diane Gashumba	(b) (6) ₁ >	Kaag Sigrid	0	6) (6), Ilona Kick	busch
	(6) (6), Suzuki Yasuhir	0		(b) (6), Vega	Morales
Jeanette	(b) (6)	, Vega Morale	s Jeanette		(b) (6)
VijayRaghavan Kris	hnaswamy	(b) (6).	, 'Skvortsov	a Veronika'	
	(b) (6)				
Cc: "MAHJOUR, Jac	ouad" () (6;>, "MINHA	AS, Raman"		(b) (6), Toomas
Palu	(b) (6) Pate Muha	med		(b) (6), Michae	l RYAN
(b) (6).	, Bernhard Schwartlän	der		(b) (6), Alex H	arris
	(b) (6), "Alveberg, E	Benedikte Lou	ise"		
	(b) (6), Ch	iaki NOGUCHI			(b) (6)·
		(b)	6 Esveld N	// Aarja	(b) (6)
Esveld Marja	(b) (6), Gonggr	ijp Mette <		(b)	, "Julie.HALL"
(Ь	(6), Kanarek Morgan		(b) (6)., M	arston Hilary	
	(b) (6), Omar Abdi		(b) (6), Ame	lie RIOUX	
	(b) (6) Tore Godal		(b) (6) "GAE	BEDAVA, Tsira"	
	(b) (6) "ROSS, Alex"	(b) (6).	, Banks Lynı	1	

			(b) (6) Conr	ad Jane
	(b) (6), Conrad Patri	cia	(b) (6), Del So	
			(6) Gahungu Zacharie	
	(b) (6). H	larikumar M K		ம்) டு, Harikumar M K
<office-nsa@nic< td=""><td>.in>, Kabagire Christ</td><td></td><td>(b) (6)</td><td>, KITA Yosuke (b) (6)</td></office-nsa@nic<>	.in>, Kabagire Christ		(b) (6)	, KITA Yosuke (b) (6)
vollice page lile	, Rabagire enrise	ille _	(b) (6) Teresa de V	
	(b) (6)	"MURIUKI, Hilda		(b) (6), Muzenda
Sindiso		, Sarah Belmir		YU Bai
The transfer over the second) (6) Kirsi Madi	(b) (6)	(b) (6	
, C			(b) (6)	2
Cubinet DE TIM	(b) (6) , 'Oleg Sonin		N. D. Williams	ft CDNAD Ctatamant
on 2019-novel c	10	e from GPIVIB Co-	Chairs: review of dra	art GPMB Statement
Dear Gro and As				
As requested plea	ase see attached			
Best,				
Jeanette				
From: GPMB Secr	etariat	(b) (6);>		
Sent: martes, 28	de enero de 2020 9:09			
To: As Sy Elhadj	(b) (6); Bi	rundtland Gro Harl	em	(b) (6); Dzau Victor
<vdzau@nas.edu< td=""><td>>; Chris.Elias</td><td>40</td><td>(b) (б); Farrar Jeremy</td><td></td></vdzau@nas.edu<>	>; Chris.Elias	40	(b) (б); Farrar Jeremy	
	(b) (6) >; Fauci Anth	2.000 (0)	(6) (6); Fore Henriet	
Gao Fu	(b) (6) >; Gashumb		(b) (б); Kaag Sig	
Ilona Kickbusch <	(b) (9; Suzuki Yasuhiro		(b) (6); Vega
Morales Jeanette		THE RESERVE TO SERVE THE PARTY OF THE PARTY	orales Jeanette	(b) (6) >;
VijayRaghavan Kr			vortsova Veronika'	(b) (6)
Cc: MAHJOUR, Jac	S	ъ) (6); MINHAS, Ran		(6); Toomas Palu
	(b) (6); Pate Muhame		(b) (б);>; RYAN, Micha	
(b) (6); SCHWARTLANDER,		(b) (6);>;	Alex Harris
	(b) (6); Alveberg, E			(b) (6); Chiaki
NOGUCHI		(b) (6); Esveld Marja		(b) (6) >; Esveld Marja
	(6); Esveld Marja		nggrijp Mette	(b) (6);
Julie.HALL	(b) (б); Kanar	74777777777 7 47773	(b) (6); Marst	
	(b) (6); Omar Abdi		(6); Amelie RIOUX	(b) (6);
Tore Godal	(b) (6); GABE	DAVA, Tsira	(b) (6); ROSS	S, Alex
(b) (6):\	The second secon			
Conrad Jane	; Banks Lynn	nrad Patricia	(b) (6); Block Bruce	(b) (б) Del Sol Dinia

(b) (6) >; Gahungu Zacharie

(b) (6) >; Harikumar M K < (b) (6)

(b) (6); Muzenda Sindiso

(b) (6)

de Vega Teresa

(b) (6); Diao Fay

Kabagire Christine

(b) (6); Harikumar M K

(b) (6); MURIUKI, Hilda Wairimu

(b) (6); Sarah Belmir (b) (6); YU Bai (b) (6); Kirsi Madi (b) (6); 'Oleg Sonin (b) (6)

Subject: TIME SENSITIVE Message from GPMB Co-Chairs: review of draft GPMB Statement on 2019-

novel coronavirus Importance: High

Dear Board members,

Thank you to all who participated in yesterday's teleconference call regarding the novel 2019-Coronavirus outbreak.

We received excellent updates from WHO and from Professor Gao.

There was consensus for the GPMB to issue a statement supportive of countries' (especially China) and WHO response efforts, and to call for urgent actions to further strengthen global preparedness and response to this outbreak.

Please find attached a draft GPMB Statement.

We ask that you please send us any feedback (preferably in track change mode) no later than <u>1700</u> Wednesday 29 January, Geneva time

Thank you very much.

Kinds regards,

Gro and As

From:	Fauci, Anthony (NIH/NIAID) [E]	
Sent:	Fri, 24 Jan 2020 11:16:47 +0000	
To:	Jeremy Farrar	
Cc:	Collins, Francis (NIH/OD) [E] (6) (6)	
Subject:	RE: nCo-V	
8		
Jeremy: Thank you for let	tting me know. Very sad and a great loss. Every day is a blessing.	
Best,		
Tony		
From: Jeremy Farrar	THE SAME STREET, STREE	
Sent: Friday, January	\$13.00 BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB	
To: Fauci, Anthony (I Cc: Collins, Francis (N		
Subject: Re: nCo-V	(IIII) OD) [E]	
Tragic news - Pete	Salama died last night, life is very fragile - what a loss.	
On 23 Jan 2020, at	: 20:32, Fauci, Anthony (NIH/NIAID) [E] (b) (6) > wrote:	
Jeremy:		o) (5)
As the second se	is well with you. Happy New Year! I, like you,	, (-)
	(t	b) (5)
	(b) (5) I do not necessarily agree with that opinion. We have a	
rapidly avalying	outbreak with the epicenter in Wuhan, but with multiple cities i	
		(5)
China and multip	ple countries in Asia involved. (b)	
Best regards,		
Tony		
•		
Anthony S. Fauci, M	MD	
Director		
	f Allergy and Infectious Diseases	
Building 31, Room 31 Center Drive, MS		
National Institutes		
Bethesda, MD 2089		

Phone: (b) (6) FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jeremy Farrar (b) (6) >

Sent: Thursday, January 23, 2020 2:03 PM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Richard Hatchett

(b) (6)

Subject: nCo-V

Tony

Happy New Year!

Difficult to understand the advice from the Emergency Ctte at WHO.

Reach out if anything – best wishes Jeremy

Wellcome exists to improve health by helping great ideas to thrive. We support researchers, we take on big health challenges, we campaign for better science, and we help everyone get involved with science and health research. We are a politically and financially independent foundation.

The Wellcome Trust is a charity registered in England and Wales, no. 210183. Its sole trustee is The Wellcome Trust Limited, a company registered in England and Wales, no. 2711000 (whose registered office is at 215 Euston Road, London NW1 2BE, UK)